Podcast appearances and mentions of eric klein

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

MONOLOGUE Chantal Kreviazuk's Anthem Debacle: Arrogance, Hypocrisy, and a Cringe-Worthy Protest NEWSMAKER Chantal Kreviazuk's Version of O' Canada Causes Huge Controversy https://torontosun.com/news/national/warmington-for-once-perhaps-the-booing-of-our-national-anthem-was-justified  Joe Warmington Toronto Sun Columnist OPEN LINES THE SOFA CINEFILE Nick Soter reviews the 1953 Romantic Comedy, Roman Holiday, starring Audrey Hepburn and Gregory Peck THE LIMRIDDLER Faustian Form  Lifestyle astray from the cultural norm. Medieval movement for Christian reform. Czechia's pride On its westerly side. Rhapsody written in Faustian form? MONOLOGUE The Vaccine-Autism Cover-Up: A New Study Just Shattered the Narrative—And They Can't Hide It Anymore NEWSMAKER Trudeau's high-speed rail to be built by SNC-Lavalin rebranded as AtkinsRéalis https://www.westernstandard.news/news/trudeaus-high-speed-rail-to-be-built-by-snc-lavalin-rebranded-as-atkinsr%C3%A9alis/62368  Jen Hodgson is a journalist with The Western Standard STEELHEADS TALK  Brendan Lang, Brampton Steelheads Play by Play and Colour Commentator Host of Trout Talk and TIPS here on Sauga 960 AM THERE'S SOMETHING HAPPENING HERE! Chantal Kreviazuk Re-imagines O' Canada – Is she a hero or a zero?   Greg Carrasco – Host of The Greg Carrasco Show, Saturday mornings 8-11am on SAUGA 960 AM THE LIMRIDDLE ANSWER AND WINNERS  Faustian Form  Lifestyle astray from the cultural norm. Medieval movement for Christian reform. Czechia's pride On its westerly side. Rhapsody written in Faustian form?   The Answer to this week's Limriddle was: Bohemian The first 5 to answer correctly were: 1. Sue Somerville, Calgary, Alberta 2. Nicholas Cole, Toronto, Ontario 3. Andrew Blair, Toronto, Ontario 4. Linda Blee, Oakville, Ontario 5. Eric Klein, Lake Worth, Florida Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode gives listeners a primer on Learning and Development (L&D) initiatives at Georgia Tech and Georgia Tech Research Institute (GTRI). Hosted by Eric Klein, the episode features insights from Dr. Diamond Ford, Senior Director of Employee Experience and Development, and Ms. Sarah Cockrell, Director of Employee Development and Culture. The discussion underscores the vital role of L&D in fostering organizational success, innovation, and employee engagement, highlighting Georgia Tech's commitment to creating a collaborative and supportive workplace.

In this episode of the New England Soccer Journal's 'The Goal' podcast, hosts Matt Langone and Matt Doherty sit down with Eric Klein, New England Revolution II midfielder and the Revolution Academy Player of the Year for the 23-24 season. Klein opens up about his journey from Pennsylvania to the Revs Academy, highlighting the honor of his award and the significance of adaptability on the field. The episode delves into his physical and skill development, the importance of fitness, and the challenges of professional soccer. Notable discussions include the value of mentorship, the nuances of player-coach relationships, and parental support in youth sports. The conversation is enriched with Klein's personal soccer memories, aspirations, and the essential qualities that make a great coach. Topics 00:00 Introduction and Welcome 00:31 Meet Eric Klein: Revolution Academy Player of the Year 01:05 Eric's Journey and Achievements 03:39 Life in the Academy and Residency Program 06:08 Transition to Professional Soccer 10:45 Personal Growth and Future Goals 17:54 Producer David's Toughest Questions 18:38 Memorable Soccer Moments 22:39 Advice for Soccer Parents 27:17 Qualities of a Good Soccer Coach 31:27 Closing Remarks and Farewell

This episode focuses on the International Food Automation Networking (IFAN) Conference at the Georgia Tech Research Institute. The IFAN Conference focuses on Robotics and Automation in the food industry and examines new technology trends, industry challenges, and evolving research. The conference brings together industry leaders from across the globe for two days of education sessions and networking opportunities. The conference is organized by the Georgia Tech Research Institute (GTRI); FAN Limited; and BMC, UK. Targeted toward corporate food manufacturing engineering leaders, equipment suppliers, and end customers of such technologies, the IFAN conference seeks to provide meaningful networking opportunities, highlight tangible research and development activities, and provide a broader context for automation deployment in the food manufacturing sector. The episode includes live interviews conducted by GTRI Researchers Stephanie Richter and Eric Klein with attendees during the IFAN event.

Like the Line 6 Helix? This man is THE product owner and design architect. He tells us all he can about Helix and the future!More info can be found at my website www.SteveSterlacci.comCheck out my Sweetwater landing page for all the gear used in my studiohttps://sweetwater.sjv.io/jrLZW0Watch on YouTube https://www.youtube.com/@SteveSterlacci/videos

In this episode, Dr. Geo engages in a detailed discussion with Dr. Eric Klein, a leading expert in prostate cancer. They delve into the genetics behind prostate cancer, exploring genetic predispositions and the mechanics behind genetic mutations. The conversation highlights the emerging role of liquid biopsies in detecting and monitoring prostate cancer, with Dr. Klein explaining the potential of next-generation sequencing in identifying DNA mutations and cancer signals in the bloodstream. They also discuss the utility and limitations of tests like Gallery's GRAIL and the influence of methylation and gene mutations on cancer behavior. Emphasis is placed on understanding cancer biology for more targeted treatment, integrating biologic signals with clinical staging systems, and the future implications for patient care and treatment monitoring. Tune in for an in-depth look at how genetics and innovative technologies revolutionize prostate cancer diagnosis and treatment.-----------Thank you to our sponsors.This episode is brought to you by Mr. Happy products-formulated by Dr. Geo Espinosa, these products address age-related health concerns like BPH and declining sexual health. By boosting nitric oxide levels and providing antioxidant support, Mr. Happy products help improve cardiovascular health, energy levels, cellular health, sexual health, mood, and stress levels. Experience the benefits of Mr. Happy products and visit > IamMrHappy.com This episode is also brought to you by AG1 (Athletic Greens). AG1 contains 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, nervous system, immune system, energy, recovery, focus, and aging. All the things. Enjoy AG1 (Athletic Greens).----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines:XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement Store____________________________________DISCLAIMER: This audio is educational and does not constitute medical advice. This audio's content is my opinion and not that of my employer(s) or any affiliated company.Use of this information is

Pixelated Audio is back from a wonderful weekend at VGMCon in Minnesota! Gene was slated to represent us but along the way drummed up a party including Pernell from Rhythm and Pixels, Carlos from Heroes Three, and Thomas Kresge head of the Game Brass (check out their new album Barrel Brassed)! When in Minnesota do as the Minnesotans do, as the saying goes. We had a fun time talking about all manner of VGM related to the Midwest; the region itself, games about the area and made there, as well as composers from the area. Getting more specific we cover pinball and edutainment in some level of depth before the panel devolves into talking about Shrek, cheese, and endless trips cross country. It's a fun journey through a diverse range of VGM and we hope you enjoy the show we put together. Pardon the noise in the background, it was the best we could do with a portable recorder. Track list 0:00:00 (Bedding) "The Creek" WolfQuest (Minnesota Zoo & Eduweb 2007) by Tim Buzza, additional music by Ben Woolman 0:14:52 (Excerpt) Suzanne Ciani Creates the Soundtrack for a Pinball Machine YouTube 0:15:51 (Excerpt) Xenon gameplay (Bally 1980) all audio by Suzanne Ciani (video courtesy of London Pinball) 0:18:19 "Main Theme" Pin-Bot (Williams 1986) by Chris Granner 0:22:24 "Speak Softly, Love" feat. Slash from The Godfather Pinball (Jersey Jack Pinball 2023) by Thomas Kresge 0:26:38 "New York City (Action)" X-Men Legends (Raven Software 2004) by Rik Schaffer 0:33:34 "Title Theme" Oregon Trail Deluxe (MECC 1993) by Lon Koenig and Larry Phenow 0:36:47 "Gimme Mo' Torque" Vigilante 8: 2nd Offense (DC version, 1999 Luxoflux) by Christian A. Salyer, Eric Klein, Javier Marquez 0:40:26 "Tracking Trouble" Puzzle Agent (Telltale Games 2010) by Disasterpeace / Richard Vreeland) 0:47:04 "Granny Cream's Hot Butter Ice Cream" Hypnospace Outlaw (Tendershoot 2019) by Hot Dad / Erik Helwig / "Chowder Man" 0:49:11 "Kitchen Music" I Am Bread (Bossa Studios 2014) by Black Heron (Leo Chilcott and Murugan Thiruchelvam) 0:54:48 "Protector's Enclave" Neverwinter (Cryptic Studios 2013) by Kevin Manthei 0:58:44 “Let's Break Physics (Main Theme)” Unstable Scientific (Studio Castle Soodalkov TBD) by Super Marcato Bros 1:04:29 "Exploration" WolfQuest by Tim Buzza 1:21:09 "The Creek" WolfQuest by Tim Buzza Additional things mentioned during the talk Minnesota Educational Computing Consortium (MECC) The Story of The Oregon Trail - Gaming Historian YouTube Trailheads: The Oregon Trail's Origins - Twin Cities PBS Ben Hanson travels the roguelike Oregon Trail - Video Game History Foundation R. Philip Bouchard (lead designer of the 1985 Oregon Trail) Personal website | died-of-dysentery.com | Died of Dysentery book, history of the game Minnesota things! Level with Emily Reese podcast home | PA episode with Emily VGMCon Games Done Quick Other things mentioned Airport CEO - game | soundtrack Fight'N Rage - game | soundtrack SML Podcast

A longtime associate of Kill, the relationship between Klein and NM State's head coach stretches back to 1994 when the two were on the same football staff at Saginaw Valley State.Klein's most recent collegiate stop came at UCONN in Storrs, Conn., where he was the director of football strength & conditioning for a period of time beginning in January of 2017.From 2010 until the early stages of 2017, Klein's services were called upon by Minnesota of the Big Ten. As the head strength & conditioning coach for the Gophers' football team, the squad made significant strides in strength, agility and endurance which have positively impacted their competitive performances.For three years prior to joining the Gopher staff, Klein served as the Director of Sports Performance at Northern Illinois, where he oversaw sports performance for all 17 sports.Klein coached at Southern Illinois from 2001-07. During his time at Southern Illinois, Klein designed the strength and conditioning programs for the five-time Missouri Valley Conference Champion Saluki men's basketball team and the three-time Gateway Conference Champion football team. Klein also helped design a new strength and conditioning center while he was at Southern Illinois.Prior to taking on the strength and conditioning program, Klein coached the defensive line at SIU in 2000 and 2001. Klein coached the defensive line and implemented the strength and conditioning program at Emporia (Kan.) State from 1999-2000. The NCAA Division II level is where Klein started as he signed on with Saginaw Valley State to be the Cardinals' assistant coach for both football and track & field from 1994-99. Along with his coaching duties, Klein designed and created the strength & conditioning program for the University Center, Mich., institution.Klein's certifications include a Strength and Conditioning Specialist from the National Strength and Conditioning Association, a USA Weightlifting Club Coach from USA Weightlifting and Speed and Explosion from the National Association of Speed and Explosion.A native of Apple Valley, Minn., Klein earned his bachelor's degree from Carleton College in 1993 before secure his master's degree from Emporia State in 2000. He and his wife, Allison, have two daughters, Taegan and Torin.

I was so grateful to sit down and record with my teacher, Eric Klein, the founder of ​Wisdom Heart​ along with his wife, Devi. I wanted you to hear from him what he's teaching me about my body, mind, spirit, and the way that those interact with the experiences I have in my marriage, my earning, my business -- pretty much in every area of my life.I am thrilled for you all to hear Eric talk with us about some of the ways that you can apply planetary astrology, the chakras, meditation, and the spiritual path in general to evolve more of what you want in love and life.In this episode, you'll hear about:Both of our journeys with Kriya Yoga and it's relevance for practitioners seeking coherence and wholeness in their busy lives. The power of practice and why it resonates with me and so many other womenThe connection between planetary astrology and our inner chakrasOur definition of intimacy and how it can show us our greatest teachersAnd more.  “Intimacy is another word for awakening  because it's really reducing the layers of self protection  in order to become more and more connected to life. The most potent aspects of life come to us as human beings.” -Eric KleinI hope that you feel as nourished and inspired as I do after hearing from Eric. My wish for you is that you receive life's gentle, insistent, invitations to more fullness and wholeness.Learn more and connect with Eric at wisdomheart.com or @wisdom.heart on Instagram!If the conversations on this podcast are resonating for you and you want to create the love, sex, and aliveness you desire with more ease, I invite you to enter a deeper relationship with me, through private coaching or my group mentorship program. Either way, you get powerful tools, conversation cheat sheets, meditations, and my loving and skillful attention every month, so your capacity for the pleasure and joy you want grows, continuously. CLICK HERE to apply for a consultation. If the conversations on this podcast are resonating for you, please leave a rating and ideally a review on your favorite podcast platform.Ready to bring about a transformation in your relationship to yourself, your body, and your partner? CLICK HERE to apply for a consultation.

On the latest edition of The Collective we are joined by Director of Sports Performance for New Mexico State University, Eric Klein. During the episode we discuss the strength coach and sport coach relationship, the importance of development for interns and athletes alike, and how passion drives high quality coaches.

JCO PO author Dr. Eric Klein shares insights into his JCO PO article, “Performance of a Cell-Free DNA-Based Multi-Cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancers” Host Dr. Rafeh Naqash and Dr. Klein discuss how a multi-cancer detection test may facilitate workup and stratification of cancer risk in symptomatic individuals. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.   Today, we are excited to be joined by Dr. Eric Klein, Emirates Professor and Chair at the Glickman Urological and Kidney Institute at the Cleveland Clinic Lerner College of Medicine. Dr. Klein is also a distinguished scientist at Grail and author of the JCO Precision Oncology article titled "Performance of a Cell-free DNA-based Multi-cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancer."   Our guest's disclosures will be linked in the transcript.  For the sake of our conversation today, we'll refer to each other using our first names. It's great to have you here today, Eric, and welcome to our podcast.  Dr. Eric Klein: Thanks, Rafeh. I'm happy to be here. Dr. Rafeh Naqash: So today, we're going to try to delve into this very interesting paper. We've had a couple of very interesting podcasts on liquid biopsies, or plan to have a few more. And this is a different aspect of liquid biopsy assessment, and the context here is early cancer detection. Now, the story as it starts, is based on the methylation profile of cancer. Can you tell us, for the sake of our listeners, as we have a very broad audience ranging from trainees to community academic oncologists, what do you understand by methylation profile on a cancer? Dr. Eric Klein: Sure. Happy to start with that. There are lots of cancer signals in the blood. Cancer cells secrete or otherwise supply the bloodstream with DNA that has methylation signals that are specific to cancer. That's a hallmark of cancer-specific mutations. You can look at chromosome fragments, you can look at proteins and mRNA and exosomes and that sort of thing. In Grail's development study, we focused on using methylation because that, as I mentioned, is a fundamental process. A fundamental property of cancer cells is altered methylation. And in our original development studies, that was the strongest signal, the one that allowed us to have the lowest limit of detection when cancer was present, and the one that allowed us to have the best predictive accuracy for the cancer signal origin. Some people think about that as predicting the tumor origin or the tumor type. And that's the basis of Grail's assay, a pan-cancer methylation profile. Dr. Rafeh Naqash: Excellent. And now to understand some of the methodology that you used here, before we go into the details because there's a lot of sensitivity and specificity obviously associated with any cancer detection test, and you want a high sensitivity and specificity. And the idea here is that this would help in triaging patients appropriately using this non-invasive tool. Could you tell us the patient population that you were trying to enroll in this study? And I think there is, again, background to other studies that you have done using the Grail test. Could you put that into context of this specific study?  Dr. Eric Klein: Sure. The population in this particular publication was from substudy 3 of a much bigger study called the Circulating Cell-free Genome Atlas, or CCGA. That was a discovery, refinement, and validation study of this methylation-based signal. And in total, all three substudies together was about 15,000 people, and it was a case-control study. About 10,000 of the individuals enrolled had cancer and about 5000 were not known to have cancer and served as controls. In the first part of the study, substudy 1 of CCGA, we simply asked the question: In individuals with known cancer, could we detect a methylation-based signal? And the answer was ‘yes'. The second question was: In patients not known to have cancer, did we not see a signal? And by and large, the answer was ‘yes'. The second substudy was a refinement and validation of the original methylation-based test. And then this study, what we refer to colloquially as CCGA3, or substudy 3 of CCGA, was the final validation that underlies the methylation assay that is currently on the market.   So, in CCGA3, we determined what the performance characteristics of this test were in a case-control fashion, and what we found, importantly, was that the specificity was very high, at 99.5%, which means the false-positive rate is only half a percent. We found that the overall sensitivity for detecting cancer varied by stage, but when you included all stages 1 to 4, the overall sensitivity for detecting known cancers was about 51%. We found that the ability of this methylation-based test to predict the correct cancer signal origin was right around 90%. And finally, the final performance characteristic was really important, which is the positive predictive value. So in individuals who had a positive signal detected, the positive predictive value was 43%, which compares very favorably to existing screening tests, all of which are below 10%.  That was the background, and the development there was focused on eventually developing a test that will screen the general population, the asymptomatic population, at risk for developing cancer. This is a subset of CCGA3, or the substudy 3 of CCGA, where we looked at the performance characteristics of this test in individuals who had symptoms that could possibly be due to cancer and individuals who had underlying medical conditions that could result in a false positive, and individuals in particular over age 65, because the risk of cancer goes up over age 65. Dr. Rafeh Naqash: Thank you for explaining that. So, again, going to some of the finer details in this study, you mentioned some very important numbers here, 99%, 63%, or something in that range for sensitivity and specificity. Could you explain a little more on that based on the cancer types? As you mentioned, stage 4, when I read the paper, has more true positives likely based on or related to how much cell-free DNA is released in the tumor. The tumor burden may be playing a role there. Could you explain that a little more for our listeners? Dr. Eric Klein: A cancer that sheds cell-free DNA into the bloodstream is more likely to be aggressive, and that's been shown in multiple different studies using multiple different platforms. And the reason for that is that the ability to shed cell-free DNA into the bloodstream goes along with biologic processes that we know are related to tumor aggressiveness. So that's a higher mitotic rate, it's neovascularization or the angiogenic switch, it's the ability to be an invasive cancer. And so the fact that you can detect cell-free DNA in the bloodstream implies some degree of biologic aggressiveness, which is not to say that tumors that shed cell-free DNA into the bloodstream are not curable. They are, in fact, curable at the same rate as cancers in people who are not tested for cell-free DNA. We know that for sure. It's just a signal that is there for us to exploit for the detection of cancers in asymptomatic individuals. And the hope is when we screen the general population, the general asymptomatic population for cancer, as we do with mammography and colonoscopy and PSA and so forth, that we can detect cancers at earlier stages, when they are far easier to cure. So I mentioned in CCGA3 that the overall sensitivity across all stages for detecting the presence of known cancers was 51%. That varied from about 16% for stage 1 cancers to 40% for stage 2 cancers to over 80 and 90% for stage 3 and 4 cancers. Dr. Rafeh Naqash: Right. And again, to provide more background to this, what we've come to understand gradually, as you mentioned, is that shedding is an important event in cancer trajectory. Do you think detection of cancers that are likely positive, driver mutation positive, have a lesser tendency to shed and maybe resulting in lesser tendency to earlier detection also, or is that not something that's true?  Dr. Eric Klein: No, I don't think it has anything to do with the presence of driver mutations. The methylation signal that we see is a reflection of the perturbation of methylation in normal cells. So normal cells turn genes on and off using methylation. That's well known. Cancer cells exploit that biologic process of methylation by - in a gross oversimplification, but in a way that makes it understandable - they use methylation to turn off all the genes that prevent cell growth and turn on all the genes that allow cells to proliferate and get all these other biologic properties that make them invasive and so forth. So it's really important to understand that the test that was used in this study and that was developed in CCGA3 measures a shared cancer signal across multiple different cancer types. In CCGA3, we were able to detect more than 50 different individual kinds of cancers. It's a shared cancer signal that is fundamental to the biology of cancers, not just a specific cancer, but cancers.  Dr. Rafeh Naqash: I see. I think what I was trying to say, basically was, when we do liquid biopsies in the regular standard of care clinic, and you're trying to assess VAFs or variant allele frequencies for a certain mutation, you tend to see some of these BRAFs or EGFRs that are very low VAF, and the data that I've seen is that you treat irrespective of the low VAF, if it's a driving mutation process. If your VAF is 0.1%, you still treat it with a targeted inhibitor. The context that I was trying to put into this is it all depends on shedding. So this liquid biopsy that we currently use, whether other platforms that are out there, if you're not shedding as much cell-free DNA or circulating tumor DNA, you're probably not going to catch that subclone or clone that is a driver. So, does that play a role in your test also? If you have, let's say, a lung cancer that is an EGFR stage 4, if the shedding is low, following a general conceptual context that these driver mutation-positive tumors do have less shedding in general than the non-driver mutation-positive, would you think that would somehow impact the detection using your test or your approach? Dr. Eric Klein: So, generically speaking, any test that looks for a cancer signal in blood is going to have a lower limit of detection. So there are analytic variables that make it such that, if you have extremely low levels of cell-free DNA or your other target shed into the blood, it's not going to be detected by the test. That's an analytical issue. Having said that, it's important to distinguish the fact that this test that we're developing isn't really a liquid biopsy. A liquid biopsy, really, if you think about it, is on patients who have known cancer, and you're doing a biopsy of the blood to determine if you can see a signal in the blood. This test has been developed to screen asymptomatic individuals who are at elevated risk of cancer, who actually may not have cancer. So we don't really view it as a liquid biopsy. But conceptually, you are correct that every test is going to have an analytical lower limit of detection so that not every tumor that sheds minuscule amounts of cell-free DNA will be detected. But that's not really relevant to this particular paper, I would say. It's not really relevant to the performance characteristics that we saw in this population. Dr. Rafeh Naqash: Understood. Thank you for differentiating the usual liquid biopsy approach that we use currently in the clinic, and this approach, which is meant more for detection in asymptomatic individuals.  Going to some of the results, could you highlight some of the interesting findings that you had in this paper as far as performance is concerned? Dr. Eric Klein: Sure. Let me put it in a clinical context because we were just discussing asymptomatic individuals. That's what the test is ultimately meant for - screening asymptomatic individuals. But a common problem in oncology is this: patients present to primary care physicians with vague or nonspecific symptoms. Someone with COPD, for example, who presents with a cough, the cough could be due to the COPD, but if they have an underlying lung cancer, the cough could also be due to the lung cancer. Or someone presents with GI symptoms, could be related to cancer, or it could be related to a whole host of other things. And so there is a challenge for primary care physicians to sort out who might have cancer and who does not, particularly if they present with vague symptoms. In fact, most cancer diagnoses in the United States and Great Britain are actually found by primary care providers.   In this paper, we looked retrospectively, after the fact, in CCGA3, the case-control study that we did, to see how this methylation-based test performed in individuals who had symptoms that could be associated with cancer, or could be due to cancer, or might not be, might be due to other things. What we found was that the performance characteristics were as good or better in this symptomatic population, where the physician is facing a diagnostic dilemma, as they were in the asymptomatic population. This is really important, specificity false negative rate across all the patients in the study was the same as it was in CCGA3. It was 99.5%. Again, the false positive rate was only 0.5%. We found, however, that overall sensitivity was better in the symptomatic population, and it was 64% instead of, or as compared to 43% in the asymptomatic population. That is not surprising because some patients who present with symptoms are more likely to have cancer.   We also looked at a subset of patients who had GI cancers because that's a very, very common presenting symptom in primary care practice, and this test performs exceptionally well for detecting GI cancers. We found that the overall sensitivity was 84%. Finally, and importantly, in terms of the clinical utility of a blood-based test to detect cancer and direct a diagnostic workup, what we call the clinical signal origin accuracy - the likelihood or prediction that a positive signal was related to a particular tumor type - overall accuracy in this population was 90%. So if you had a cancer signal detected and you had a clinical signal of origin assigned to it, let's say, the test came back with cancer signal detected, the CSO prediction was GI cancer, the overall accuracy in actually finding a GI cancer was 90%. Actually, it was a little higher for GI cancers, but overall, for all cancers, it was 90%. Dr. Rafeh Naqash: You mentioned that GI cancers had a very high sensitivity, around 84% or so. Is that, again, related to the tumor shedding compared to some other tumor types?  Dr. Eric Klein: Yes, there is a broad range of shedding across tumor types. So if you look at our data from CCGA, cancers like thyroid, prostate, and kidney do not shed a lot of cell-free DNA into the bloodstream, whereas GI cancers, hematologic malignancies, ovarian and pancreatic cancers shed much more cell-free DNA, and therefore their sensitivity for detection of those cancers is better.  Dr. Rafeh Naqash: What would be the alternate approach? Your sensitivity here is 64%, which is pretty good, but it's not perfect. So the patients who potentially would be missed using this test, what would be the alternate approach capturing those patients also and hopefully avoiding a missed cancer diagnosis?  Dr. Eric Klein: Well, it would be whatever the standard workup is that a primary care physician orders for someone who has vague symptoms. So, he idea here was to develop this, what we call a diagnostic aid for cancer detection in the symptomatic population. The idea here is to make the workups more efficient and to lend a greater degree of certainty as to what the diagnostic pathway ought to be. So, if you have a patient with vague symptoms and you're not sure if they are due to cancer or not, you might order a pretty broad diagnostic evaluation that might not end up finding cancer. In fact, if you take all the patients in a primary care setting, only about 7% of those individuals have cancer. Whereas, if you have a blood test that has a sensitivity of 64% and a positive predictive value of 75%, and you did that blood test early in the diagnostic workup and it was positive, you can do a much more tailored and perhaps a more efficient evaluation in speeding the diagnostic resolution.  Dr. Rafeh Naqash: As you mentioned, perhaps avoid unnecessary testing, which adds to the overall cost burden in the healthcare field.   Dr. Eric Klein: Correct. This was tested in another study called SYMPLIFY, which was done in a similar population of patients as this study - symptomatic patients presenting with vague symptoms or GI symptoms or weight loss, fatigue, those sorts of things, to primary care practice in the UK. And that was a prospective study. And the performance characteristics were very similar to what we saw in this study, although the overall positive predictive value in that study was 75% if you look at all cancers. And that would be very useful to a primary care physician and a patient to know what the likelihood of their having cancer is at the time they present or within a few days of presenting. Dr. Rafeh Naqash: Absolutely. And perhaps, to complement this approach with some of the other diagnostic approaches, maybe the possibility of detecting cancer earlier increases. So this is likely complementary and not necessarily the one-stop-shop. Dr. Eric Klein: It's important to understand that even in the symptomatic population, this is a screening test. And so, like all screening tests, if you have a positive mammogram that shows a nodule, you need to have a diagnostic workup to prove whether or not you have cancer. This blood test does not make the diagnosis of cancer; it simply helps direct a diagnostic evaluation that's necessary to confirm whether or not cancer is present or absent. That's true for both the asymptomatic and symptomatic populations. Dr. Rafeh Naqash: Could you tell us a little bit more about the CSO prediction in the general context of oncology and NGS, or the whole transcriptome sequencing that we do these days? We often see on a report that says,“What is the likely tumor of origin?” if you have an unclear primary. Can you explain that in the context of the approach that you guys use for CSO prediction? How does it differ from methylation versus mRNA prediction of tumor of origin or cell of origin?  Dr. Eric Klein: Methylation has a rich signal in it, and it can distinguish cancer cells from a non-cancer signal, and using a second algorithm, specific methylation patterns that are specific to given lineages can identify lung cancer versus colon cancer versus liver cancer.  Dr. Rafeh Naqash: Understood. Do you see this as becoming an approach that could be used, using, for example, urine or other sources that we can easily acquire versus blood? Dr. Eric Klein: Possibly. There is a lot of work in the field looking at urine-based markers for cancers, particularly, obviously, urologic cancers. And so there are already some products on the market made by other companies using methylation and other specific mutation patterns, for example, in urine to detect bladder cancer and to determine bladder cancer aggressiveness. It is an area of active investigation.  Dr. Rafeh Naqash: This is definitely an exciting field, and the way the entire field of liquid biopsies in general is moving as it's detecting cancers or identifying mutations, and then implementing appropriate approaches, whether it is more screening or more treatment and all the drugs, etc.  Are there any other interesting future approaches that you guys are planning as part of this paradigm shift that I envision will hopefully happen in the next few years?  Dr. Eric Klein: Yes, as a company, Grail is focused on using this methylation-based technology across the entire cancer spectrum. So that's screening asymptomatic individuals, it's helping to direct diagnostic workups in individuals who present with symptoms to primary care practice, and also in the post-diagnostic space and all the possible uses there. So the detection of minimal residual disease and the decision on whether or not additional treatment is necessary, predicting response to particular therapeutic agents, or even choosing the correct therapeutic agents. All of that is under development. Dr. Rafeh Naqash: Definitely exciting. Now, the last portion of this podcast is specifically meant to highlight your career and know a little bit more about you. Could you tell us about your career trajectory and how you shifted focus towards a biomarker-driven approach?  Dr. Eric Klein: Sure. Biomarkers have been a part of my career for a long time. I am trained as a urologic oncologist and did my residency in urology at the Cleveland Clinic and a fellowship at Sloan Kettering. At the dawn of the molecular biology era, the lab I worked in bought one of the very first PerkinElmer RT PCR machines for $5,000. It took up a whole desktop. I got very interested in genomic science at that time. So I spent well over 30 years practicing urologic oncology at the Cleveland Clinic, primarily focusing on prostate cancer. In the course of my career, I had the opportunity to work on a number of blood-based, urine, and tissue-based biomarkers. I have always been interested in understanding how our ability to measure molecules in blood and urine can help improve patient outcomes either through a streamlined diagnostic process or understanding of the biology of the disease better, picking the appropriate therapy, and so forth.  In the course of that, I worked with someone at a company called Genomic Health in developing  a biopsy-based RT PCR gene expression assay that helped select men for active surveillance. That individual subsequently joined Grail and he came knocking on my door in 2016 when Grail was just getting started to tell me about this exciting new technology. He said, “This isn't about urologic cancers in particular, but would you be interested in helping us accrue patients for this big clinical trial we're doing, CCGA, and determine if this technology would be useful in some way in helping patients.” And being the curious individual that I am, I said, “Sure.” And so I helped accrue lots of patients to CCGA. The results were shared, and I was quite excited by them and continued to work with the company on other studies, including PATHFINDER and some others, and eventually became a consultant for them.  When I reached what I thought was the end of my clinical career by choice, I decided to step away from clinical practice, I had the opportunity to join Grail as a scientist, and that's where it's been. And what I would say, in the big picture, is this: as a surgeon, I was able to help a lot of patients on an individual basis. So I did about 10,000 major cancer operations in my career. So I helped those 10,000 people. As an academician, I was able to make certain observations and publish them in a way that taught people about different kinds of surgical techniques and how they may work better, and so I was able to expand my impact beyond the patients that I actually touched.  When I heard about and understood what Grail was trying to do, I thought, “Wow, if we could develop a screening test that detects lots of cancers that we don't screen for - about 70% of all cancer deaths in the US are from cancers that we have no screening tests for - and if the screening population in the United States, individuals between ages 50 and 79, that's how CMS defined screening populations, well over 100 million a year, if this works, think about the impact that that could have.” That is really why I got excited about it. It fit my scientific interest, and I could see the big picture.  Dr. Rafeh Naqash: Thank you for giving us some insights about your personal career. It is definitely a very interesting topic. I learned a lot, and hopefully, our listeners will find it equally interesting. Thank you again for being here today.  Dr. Eric Klein: My pleasure. Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to rate and review this podcast, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and inform. It is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   The guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not reflect the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.        

Welcome to Health-e Law, Sheppard Mullin's podcast exploring the fascinating health-tech topics and trends of the day. Our digital health legal team, alongside brilliant experts and thought leaders, share how innovations can solve some of healthcare's (and maybe the world's) biggest problems, if properly navigated. In this episode, Sheppard Mullin healthcare team leader Eric Klein joins us to discuss the future of health tech and what we can expect to see in 2024.   What We Discussed in this Episode: Where is healthcare disruption expected in 2024 and how will that impact costs? Where is digital health headed in 2024? Where will it have the most significant impact? What are savvy investors looking for in 2024? How can industry players make themselves more attractive to investors? What should providers, payers, and industry stakeholders consider as they look to make tech investments? How will the expected wave of consolidation impact the digital health space?   About Eric Klein With over 35 years of practical legal and business experience, Eric Klein is widely acknowledged as one of the most experienced attorneys in population health management, physician alignment, and global risk transactions. As a partner in Sheppard Mullin's Century City Office, he leads the firm's distinguished national healthcare practice, which has been honored as a Law360 U.S. Health Care Practice Group of the Year three times in the past seven years. Over the last decade, Eric has advised on over 85 hospital mergers, acquisitions, and joint ventures, more than 85 health plan mergers and acquisitions, and many of the country's largest physician services transactions, establishing him as one of the nation's most active physician group, health plan and hospital M&A and joint venture lawyers.   About Sara Shanti A partner in the Corporate Practice Group in the Sheppard Mullin's Chicago office and co-chair of its Digital Health Team, Sara Shanti's practice sits at the forefront of healthcare technology by providing practical counsel on novel innovation and complex data privacy matters. Using her medical research background and HHS experience, Sara advises providers, payors, start-ups, technology companies, and their investors and stakeholders on digital healthcare and regulatory compliance matters, including artificial intelligence (AI), augmented and virtual reality (AR/VR), gamification, implantable and wearable devices, and telehealth. At the cutting edge of advising on "data as an asset" programming, Sara's practice supports investment in innovation and access to care initiatives, including mergers and acquisitions involving crucial, high-stakes and sensitive data, medical and wellness devices, and web-based applications and care.   About Phil Kim A partner in the Corporate and Securities Practice Group in Sheppard Mullin's Dallas office and co-chair of its Digital Health Team, Phil Kim has a number of clients in digital health. He has assisted multinational technology companies entering the digital health space with various service and collaboration agreements for their wearable technology, along with global digital health companies bolstering their platform in the behavioral health space. He also assists public medical device, biotechnology, and pharmaceutical companies, as well as the investment banks that serve as underwriters in public securities offerings for those companies. Phil also assists various healthcare companies on transactional and regulatory matters. He counsels healthcare systems, hospitals, ambulatory surgery centers, physician groups, home health providers, and other healthcare companies on the buy- and sell-side of mergers and acquisitions, joint ventures, and operational matters, which include regulatory, licensure, contractual, and administrative issues. Phil regularly advises clients on matters related to healthcare compliance, including liability exposure, the Stark law, anti-kickback statutes, and HIPAA/HITECH privacy issues. He also provides counsel on state and federal laws, business structuring formation, employment issues, and involving government agencies, including state and federal agencies.   Contact Info: Eric Klein Sara Shanti Phil Kim    Resources: Sheppard Mullin's Top 10 Takeaways from HLTH 2023 | Healthcare Law Blog Healthcare Law Blog | Sheppard Mullin (sheppardhealthlaw.com)   Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Google Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

Drs. Eric Small, Anthony Zietman, and Eric Klein share their reflections as founders of the ASCO Genitourinary Cancers Symposium and discuss key moments in the Meeting's development, its role in advancing GU cancer research, and major challenges ahead for the field as the Symposium celebrates its 20-year anniversary. TRANSCRIPT Dr. Eric Small: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Eric Small, your guest host of this ASCO Daily News Podcast today. I'm the co-leader of the UCSF Prostate Cancer Program and deputy director and chief scientific officer at the UCSF Helen Diller Family Comprehensive Cancer Center. This year, quite amazingly, we're celebrating the 20th anniversary of the ASCO Genitourinary Cancers Symposium, which is hosted annually in San Francisco. The Symposium has heralded some of the biggest strides in GU oncology and has the largest multidisciplinary, global audience for GU cancer research. I was honored to have a role in the development of ASCO GU two decades ago, along with my friends and colleagues, Dr. Eric Klein, emeritus professor and chair of the Glickman Urological and Kidney Institute at the Cleveland Clinic. And Dr. Anthony Zietman, a professor of radiation oncology at Harvard Medical School and the Massachusetts General Hospital. On today's episode, we'll be reflecting on key moments in the meeting's development, its role in advancing GU cancers and GU cancer research, and major challenges that lay ahead for the field. You'll find our full disclosures in the transcript of this episode, and disclosures of all guests on the podcast are available at asco.org/DNpod. Eric and Anthony, I'm delighted to have this opportunity to catch up with you both to discuss ASCO GU, thank you for coming on the podcast today. Dr. Eric Klein: Thanks for having us. Dr. Anthony Zietman: Thanks for the invitation. Dr. Eric Small: Well, it's really exciting and it's wonderful to see the two of you. So, the ASCO GU Symposium has been a key annual event for all of us in the GU field. But to give our listeners some background, when the Symposium was first created, when we first met in San Francisco, starting on Thursday, February 17, 2005, it brought together 1,035 individuals interested in the prevention and treatment at that point of prostate cancer alone. At that time, the meeting was co-sponsored by ASCO, the American Society for Therapeutic Radiology and Oncology or ASTRO, the Society of Urologic Oncology (SUO), and the Prostate Cancer Foundation. It was actually the culmination of several years of planning. Clearly, it represented the first truly multidisciplinary scientific and educational meeting dedicated solely to prostate cancer, and we'll come back to talk about that. The meeting went back and forth between San Francisco and Florida for a few years before finally, settling permanently in San Francisco. In the last 20 years, ASCO and the Symposium's co-sponsors expanded the meeting to include all genitourinary specialties. This year, ASCO received more than 875 abstract submissions and anticipates that there will be even more attendees than last year. On a personal note, it's truly amazing to me that here we are, 20 years later, and the meeting is going stronger than we could ever have imagined. I must say that my motivation to help organize this meeting stem from two issues that were somewhat in tension with each other. First, the field of prostate cancer and prostate cancer research was just starting to take off at the time, and we really needed, as a community, a venue where across disciplines, we could talk and meet with each other. But that was in real tension, at least at ASCO, where we were relegated at the Annual Meeting to a tiny room at the far end of the convention center on the last day of ASCO, because really, that's all we could muster. And I do remember making a pitch, assuring folks that there was an unmet need, and that the field was going to take off, who knew? So, I'm wondering, and either of you can jump in (Dr. Klein, Dr. Zietman), tell us how you got involved in the first GU meeting, and what's the most salient feature of your involvement? Anthony, do you want to start? Dr. Anthony Zietman: I think it's really important to discuss the historical context at which this meeting was born. Back in the 1990s, we were incredibly polarized as specialties in GU oncology. PSA had been introduced in the late '80s, early '90s, screening was everywhere. There was a tidal wave of patients and an almost reckless race to treatment. All surgeons believed that all patients with localized early prostate cancer needed surgery and that they could do individually, a beautiful job. And all radiation oncologists believed that they could deliver morbidity-free treatment and could do it to everyone regardless of your age or stage. And there were a few, there were a few who thought maybe we didn't need to screen everyone, and maybe there was a little bit of overtreatment, maybe we've gone a little bit too far, but those voices were really suppressed in the '90s. Those voices didn't have a voice. Many of us also believed there was more morbidity to our treatment than we'd appreciated. And that was the media in which, us three, all young research physicians, probably all in our low forties were given the charge of this meeting. And the thing I most remember about it in the planning, is that we actually decided collectively to give voice to everyone, including maverick voices. It wasn't just about the party line, and it wasn't just about the North American line, there were Britts and there were Swedes, and there were Dutchmen who had very important things to say as well, and very, very different perspectives. And we also chose to give voice to young people as well as just our party elders, so to speak. I don't know which of us, if any of us, or maybe it was our society suggested but we do it all in a single room such that rad oncs and surgeons were all together, and it led to a kind of forced truthfulness, which started to break down this groupthink that we developed in our own silo. So, when I look back, I think that that context was very important and that what we sought as young program chairs was we sort of tapped in something that was latent in our field. Eric KIein, I don't know if you remember things as I did. Dr. Eric Klein: I do. And things were very siloed then. We had hired early in the mid-90s, I think, a young radiation oncologist named Pat Kupelian, who became a close collaborator and a good friend, and who really changed the narrative around treating prostate cancer at the Cleveland Clinic, which was all surgical prior to that time. And he did such high-quality work, it was hard not to pay attention. And he actually took it on himself in his early years when he wasn't very busy to sit down and go through all the patients that we had treated with prostate cancer at the Cleveland Clinic, radiation versus surgery, and had the temerity to write a manuscript that showed that there was no difference in survival, based on PSA biochemical recurrence and metastasis and that sort of thing. And that was sort of game changing. And it really clued me into the fact that for patient's sake, we needed to be talking to our colleagues. The second perspective was from the perspective of having attended a couple of Prostate Cancer Foundation meetings. And I think they really deserve credit for increasing the visibility of prostate cancer research, and funding it and recruiting really good scientists from other disciplines. When young scientists were told, and we heard this repeatedly, "Don't spend your career researching prostate cancer, it's a dead end." And PCF did a great job of having a multidisciplinary meeting, which was smaller and not so clinically focused, but also got me excited. Dr. Eric Small: I think you're right, Eric. And I think that the transdisciplinary nature, as Anthony pointed out was new, it was innovative. No one had really, really thought about it. It was at the margins in different meetings. Your comments about PCF, Prostate Cancer Foundation, resonate because we did take a page from their book in many ways although that meeting, as you point out, is much more basic research-focused. I don't know if you guys recall that first year, in fact, PCF was a co-sponsor. We actually had asked Mike Milken to give a talk and he did. And obviously, once we expanded to the broader GU cancers, it was less pertinent for PCF to be involved. But absolutely, I agree with you, Eric, they deserve credit. PCF, and the PCF involvement, was one of the things that changed. There's many things that are constant that haven't changed, even though the science clearly has evolved dramatically. And I'm wondering if you guys can comment on things that are the same. One thing that stands out for me: I had the opportunity to look through the agenda for the 2005 meeting. And right there, very prominently, was a special lunch session that we had designed for mentorship and career development for trainees and early career investigators, and that's still ongoing and others have modeled it. And I think that was one amazing feature of this. One of you, I think Anthony mentioned that we invited a lot of young people to speak and to be the path blazers, but we also did this career development piece, and it was a wonderful event. I wonder if either of you or both of you could comment on other things that you think are constants and you anticipate will always be there. Dr. Anthony Zietman: I think to me that constant is that every time I go, I hear speakers I've not heard before. Often very senior speakers, I've never heard them before. But it is the practice of GU ASCO to invite people that are outside your sphere of experience, which is very challenging. Dr. Eric Klein: Two things strike me. I think one is the international nature of the faculty. We tried very hard (and subsequent program directors have) to be very inclusive and to bring the work that was the most cutting-edge to the stage. There are lots of things that are done in Europe that started there sooner. PSMA treatment, for example, and many other ProtecT trial and many other things. And the debates on stage and how that gave the opportunity for every subspecialty to have the opportunity to share its perspective on particular case management issues and case management conferences, I think have been around forever. And maybe, the most valuable part of it all is to hear people's perspective on how to manage a particular patient. Dr. Eric Small: I think the other comment you made Anthony that resonated and still goes on, was it was a conscious decision to have a single session in one room where everyone attended. And not to do the usual small breakouts and concurrent sessions, but sort of the philosophy being, is we all need to hear the same thing, we all need to be in the same room at the same time. And it really fostered this transdisciplinary approach; it was truly educational for us. Now, it's sort of part of what we do, and part of what our patients expect of us. I think that bringing us all together into one room was really great. Dr. Anthony Zietman: But it's now so part of what we do, but it's difficult certainly for younger faculty and for residents to believe we ever did it any other way. But we did, and I don't know whether ASCO GU led that or reflected that, but that was the zeitgeist among young individuals like us. And it's really become the culture of contemporary practice. Dr. Eric Small: So, given that that's the culture now, which it is, and I think sure, we should take credit for it, at least in GU: why then is it important for people to continue to attend GU ASCO today if it's now our culture to do that? Dr. Anthony Zietman: For me, it's because we share information as equal partners in a multidisciplinary team. And our practice is so multidisciplinary and multi-modality these days that we can't exist alone, we no longer try to. Dr. Eric Klein: Nor can we. The amount of knowledge that's being generated in each subspecialty and it's spinoffs is so great. It's impossible for a busy surgeon to stay on top of that. And this is sort of one-stop shopping for everything that's really current and appropriate to know about. And again, I always look at these things from the patient perspective, and my ability to counsel patients about what their best treatment options might be, I thought more and more dependent, and I think today more and more depends on being knowledgeable about everything that's going on, and not just one narrow field that you happen to be an expert in. And that's why I think it's so important for youngsters to attend and even oldsters like us to attend to stay current. Dr. Anthony Zietman: Yeah, and also, multidisciplinary means so much more these days. It does mean oncologists and radiologists, information technologists. I mean, who knows what it'll mean in the future, but it's always expanding. Dr. Eric Small: And I think it's interesting, back when we did this, when we started it, we were worried about being able to fill one meeting with prostate cancer information - we did easily. It was not immediately clear that there was a role or room for additional GU cancers. And then there was an explosion both in kidney cancer work at first, and then bladder cancer. And now it's unbelievable how much is there. And perhaps, this meeting needs to be twice as long. So, I agree with you guys. I think that it's the best way to stay current. The other thing that I really appreciate about this meeting and others have a hard time doing it, is that it provides, as Eric indicated, for the busy clinician. It integrates sort of the important information that's coming in terms of more basic science and makes it readily available and digestible, which isn't always the case at pure science meetings and may or may not be apparent in other meetings. I, again, was looking at the preliminary agenda in 2005, we had asked Bill Nelson to talk about molecular targets or prevention, how forward-thinking. And that's continued to be the case that this is a meeting where you get that integration from the laboratory. Dr. Anthony Zietman: Well, and I would add to that, not just the integration of it, it's where now you get to hear things first. I mean, it used to be that, you went the AUA or ASTRO or ASCO to hear things. Now, everyone one wants to present it first at GU ASCO. Dr. Eric Klein: Yes, that's correct. Dr. Anthony Zietman: And I think we actually made it permissible in the early days that you could present at GU ASCO and at your specialty meeting. Dr. Eric Small: What are the challenges in the field that are going to likely shape the content of future meetings? And we've all alluded to the fact that the meeting is evolving and has done a really good job of staying current with the clinical science. But beyond that, what do you two feel are important areas that this meeting is likely to continue to address? Dr. Eric Klein: So, biomarker development has always been an important part of this meeting, and I think we need to broaden our view of what biomarkers are now, and in the AI era, digital pathology and AI-based models that predict treatment response and outcome. My hope is that they will be studied in a rigorous fashion, and that they will end up outperforming the kind of single biomarker approach that we've used in the past. And we need to understand that; we need to understand the science behind AI to a certain level, and we need to understand what questions AI can address, and how that might be useful. But I'm particularly excited about digital pathology where sampling error becomes less of an issue and the number of potential inputs you're looking at that are related to the output should increase exponentially. Dr. Anthony Zietman: And I would add on the AI side of things, as a former journal editor, when AI papers came into the journal, we actually didn't have enough people who could review them, who had the understanding to review these papers and tell us, "Is this a good paper or a bad paper?" So, we're going to need to increase our understanding of AI, Eric, as you said. So, I think that will be a push in the years to come. Also, on a very practical level, it is such a popular meeting, keeping us all under one roof and in one room, will become just difficult. But it's part of the culture of the meeting, and I think it's what people want. Dr. Eric Small: It's a good challenge to have. Dr. Eric Klein: Feeding everybody too. I recall one constant has always been really good breakfasts and lunches. Dr. Eric Small: Right, that has been a standard of ours. One of the interesting things that I think has changed, we saw glimmers of it back in 2005, but it was early on and it was, I think very early on in sort of a good understanding of social determinants of health and equitable access to healthcare and the challenges posed by incredible technology development and making sure that that doesn't increase disparities. And I think that that focus has increasingly been present in meetings and is not going to be lost. And it also speaks, one of you spoke to our international audience, that increasingly, I think this meeting is going to address urologic oncology and how we address it not only in developed countries, but in lower- and middle-income countries. And I think that will be a focus as well. I'm excited with what the future holds for ASCO GU. It has been an incredible run. I'm hoping that we'll be able to perhaps catalog some of the salient presentations that have been done at this meeting over the years, but there's no question as both of you have pointed out, this has become the venue. Well, thank you both for sharing your insights with us today on the ASCO Daily News Podcast. Really wonderful to see you both and talk with you. Dr. Eric Klein: Great to be here. Thanks. Dr. Anthony Zietman: Great to be here. Looking forward to the next 20 years. Dr. Eric Small: That's right. Dr. Anthony Zietman: If I'm still around. Dr. Eric Klein: Yeah, let's do this again in 20 years. That'd be great. Dr. Eric Small: We will. And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use and the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Eric Small Dr. Eric Klein @EricKleinMD Dr. Anthony Zietman   Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:     Dr. Eric Small: Stock and Other Ownership Interests: Fortis, Harpoon Therapeutics, Teon Therapeutics Honoraria: Janssen Consulting or Advisory Role: Janssen Oncology, Teon Therapeutics, Fortis   Dr. Anthony Zietman: Leadership: Elsevier   Dr. Eric Klein:No relationships to disclose

This episode is the second part of a special focus of the Georgia Tech Research Podcast on the 50th anniversary of Section 504, the federal law that became the Americans with Disabilities Act (ADA). The host of this episode, J. Denise Johnson Marshall, ADA Compliance Coordinator at Georgia Institute of Technology, calls this series “a very special podcast for us at Georgia Tech.” The guests for this episode are representatives from Georgia Tech's Employee Relations Dept., Captioning and Description services, the CARES Employee Resource Group, and the Excel program. This episode is in conjunction with the creation of a special award at Georgia Tech.  As a part of Georgia Tech's commemoration of the 50th anniversary of Section 504 of the Rehabilitation Act of 1973, the Office of Equity and Compliance Programs – ADA Compliance established an award called Advocates for Accessibility. The Advocates for Accessibility award recognizes individuals who have actively worked to improve accessibility for people with disabilities in the Georgia Tech community.   The guests for this episode are representatives from Georgia Tech's Employee Relations Dept., Captioning and Description services, the CARES Employee Resource Group, and the Excel program. Thank you to our guests from Georgia Tech's Employee Relations Dept.(Langston Jackson), Captioning and Description services (Sheryl Ballenger), the CARES Employee Resource Group (Asha Hagood), and the Excel program (Kenneth Surdin), and our host Denise Johnson Marshall.   TRANSCRIPT: Announcer This is the Georgia Tech Research podcast presented by GTRI. Join us as we move forward one research story at a time.   Announcer The views represented in these interviews do not reflect the views of the organization. They are anecdotal views of individual experiences.   Eric Klein Welcome to the Georgia Tech Research Podcast presented by GTRI. This podcast highlights research and opportunities around Georgia Tech and the Georgia Tech Research Institute. Today's episode titled Beyond Compliance is in recognition of the 50th anniversary of Section 504. This is the Rehabilitation act, which became law in 1973. My name is Eric Klein and today's host is Denise Johnson Marshall.   Denise Johnson Marshall Welcome to the Beyond Compliance Podcast. I'm your host, Denise Johnson Marshall, Director of Equity and Compliance Programs and also the Institute ADA Coordinator, and I'm part of the Office of Equity and Compliance Programs. Today we'll be highlighting the individuals that are behind some of the services that you may or may not know about at Georgia Tech and GTRI that help to impact the lives of individuals with disabilities. Today you'll hear from employee relations, captioning and description services, the CARES Employee Resource Group, and finally, the Excel program. Let's take a break from this podcast to listen to more about departments that we want you to get to know.   Asha Hagood Get to know CARES ERG the CARES at GTRI Employee Resource Group is an inclusive community for employees who identify with having a visible or invisible disability, caregivers for individuals with disabilities, and allies of the community. Our mission is to create space for issues around accessibility by amplifying the conversation around accessibility inequity and by providing educational opportunities around accessibility compliance. We're seeking to grow our membership and have several cochair positions that could use your ideas and your voice as we gear up to provide information sessions and other fun events. If you're interested and are an employee at GTRI, please reach out via our contact form on Webwise. Cares and other ergs are listed there under the Communities tab.   Denise Johnson Marshall Now that you know a little bit more, it's time to get back to the podcast. Our first guest for the Beyond Compliance podcast is Langston Jackson. Langston is the HR Compliance Coordinator for Employee Relations on our campus. Welcome, Langston.   Langston Jackson Thank you for having me.   Denise Johnson Marshall Can you briefly tell us the role of your office and briefly your responsibilities?   Langston Jackson My office has several responsibilities. One of them includes the administration, Americans with disabilities reasonable accommodations process for employees. We administer that. The office is also responsible for coordinating the development of the Institute's Affirmative Action Compliance Program, as well as the administration of the university's impartial board of Review Appeals process and Procedures.   Denise Johnson Marshall That's very interesting can you tell us a little bit about what elements of an employee's job responsibilities do you consider when you're considering reasonable accommodations? And also, could you define that a little bit for us? What are reasonable accommodations?   Langston Jackson So under the ADA, a reasonable accommodation is basically a modification or adjustment to the job or the work environment that allows a person with disability to still perform the essential functions of their job. The essential functions are the major components of the job duties. Minimal parts of the job duties are not considered essential functions. It is the functions that take up a large part of the job aspects.   Denise Johnson Marshall Do you have any examples of that?   Langston Jackson Yes. For example, individual that's a courier, their essential functions may include driving, whereas your most administrative functions would not include that. That would be in office work. Accommodation for a courier would have to take into consideration driving requirements, whereas most individuals, they don't understand that ADA does not contemplate how they get to and from work. So what the ADA does take into consideration is the essential functions that they're taking when they are working.   Denise Johnson Marshall So who decides what is essential? What isn't essential? You had an example of a carrier, and it may be essential to be able to get back and forth as far as those other types of tasks. Who decides what is essential?   Langston Jackson What will happen in the accommodations process? My department will send a request for essential functions and job analysis forms to be completed by the employee supervisor. We typically ask that they return those documents to us within five business days. Those forms break down into percentages what the job duties are. We ask that they give us at least four and that the supervisor breaks them down into percentages for us to review and to consider in the accommodations process.   Denise Johnson Marshall So what should an employee with a disability expect when they're going through this process?   Langston Jackson It's an interactive process. It requires give and take from the employee, the department, and from our office. We obtain the essential functions in the job analysis forms, and a key component is another form called the medical certification form. That form gives us what the condition is. It gives us an idea if this is a temporary or permanent condition. It lets us know what the limitations are for the individual, and it also gives us recommendations for the accommodation for the employee that will help them best perform the essential functions of their job.   Denise Johnson Marshall What type of guidance does your office give to the Georgia Tech larger community, such as maybe supervisors or HR business partners?   Langston Jackson With regards to our interactions to supervisors and the HR business partners, we first and foremost try to make sure that they are aware and are sensitive to the accommodation for the employee. What we like to do with all of them is to ensure that we've gone over the process and the Americans with Disabilities act with them so that they understand certain requirements and certain things that the department will have to supply to the individual. What we often find is that individuals that haven't gone through this process before, we explain everything with regards to the essential functions, the medical certification form, and then we like to go over any questions that they may have. It's really a give and take. At the end of the day, we try to establish that the department can make their recommendations as well, and we're letting them know also what the employee is asking for.   Denise Johnson Marshall So what is the best way for an employee to contact you if they just have questions or they want to get the process started?   Langston Jackson Anyone wishing for additional information may contact the office at employe-erelations@ohr.gatech.edu. Again, that's employee-relations@ohr.gatech.edu. They can contact me directly by email at ljackson98@gatech.edu.   Denise Johnson Marshall As our listeners may or may not be aware, we are also celebrating the 50th anniversary of the Rehabilitation act of 1973. With that in mind, are there any final thoughts that you have on your office's mission and goals?   Langston Jackson As we're celebrating the 50-year anniversary of the Rehabilitation act of 1973, we recognize the many strides that have been made and that there are many more that we still can improve upon for employees with disabilities. My office is proud to continue in advancing this work forward and here to assist and guide all employees at Georgia Tech with the provision of reasonable accommodations.   Denise Johnson Marshall Langston, thank you so much for taking the time out to briefly talk about your office and what you do.   Langston Jackson Thank you all for having me. Thank you for all that you do for the employees here at Georgia Tech.   Denise Johnson Marshall Let's take a break from this podcast to listen to more about departments that we want you to get to know.   Kendra Brown Get to know the center for Inclusive Design and Innovation the center for Inclusive Design and Innovation, also known as CIDI, is housed within the College of Design at Georgia Tech. The accessibility experts at CIDI have decades of experience in user centered accessibility research and delivery of services to help individuals with disabilities. CIDI's overall mission is to improve the human condition through equal access to technology based and research driven information services and products for individuals with disabilities. With its rich history of providing accessible solutions to an underserved community, CIDI has positioned itself as a leader in accessibility and inclusion. CIDI is committed to promoting technological innovation and addressing unmet needs by providing accessible and inclusive environments for all. Maintaining dynamic partnerships with universities, state agencies, publishers, nonprofit groups, and corporations allow CIDI to continue to expand its expertise and further advocate for accessibility in Georgia, across the country, and internationally. For more information about CIDI, you can visit their website at www.cidi.gatech.edu or you can contact their customer support team by phone at 404-894-7756.   Denise Johnson Marshall Now that you know a little bit more, it's time to get back to the podcast. Our second guest today is Dr. Sheryl Ballenger. Dr. Ballenger, thank you so much for being a part of our second Beyond Compliance podcast.   Sheryl Ballenger Thank you so much for having me. I'm excited to be here.   Denise Johnson Marshall Dr. Ballenger is the Manager for Deaf and Harder Hearing Services as a part of the center for Inclusive Design and Innovation here at Georgia Tech. Dr. Ballenger, can you briefly tell us about your role within CIDI and your responsibilities?   Sheryl Ballenger Yeah, I'd love to. I am Manager of our captioning and describe media services as part of CIDI. This is a unit that started in 2011 when CIDI was interested in entering into being able to provide services for students who were deaf and hard of hearing. My background being an interpreter for the deaf one point, and also with a degree in deaf Education, made it a good fit for me. We were able to then begin having captioning for classes for students in different colleges across the Board of Regents, as well as captioning videos that were used in educational environments. First series that we actually captioned was a welding series for one of the technical community colleges in Georgia.   Denise Johnson Marshall That is very interesting. When we often see captions or audio descriptions, we know that it's there, but we really don't understand what it takes to get there. Can you tell us a little bit about that process?   Sheryl Ballenger Sure. First of all, we're going to look at video captioning or caption Media, whichever way you would like to phrase that. Basically, that involves media access. Most of the media that we do work on is for education purposes, but we also serve nonprofits and other groups that post media to their websites and want those videos captioned. There's also speech to text systems and there's two main ones that are used. The first would be CART. CART, and that stands for communication access, real time translation. This requires a skilled stenographer who's using a stenotype machine and is writing at a near verbatim speed. No matter how fast the speaker is speaking, they're keeping up with them. And then another speech to text system that we use is called either Cprint, the software or Typewell. This type of captioning is meaning for meaning. The Cprint software was developed by National Technical Institute for the Deaf. They developed the Cprint software about 20 years ago or so in a way to make sure that there was a meaningful way for captions to happen for deaf students. The Cprint software actually uses a qwerty keyboard and is something that most people already have skill with to be able to provide once they do CPrint training.   Denise Johnson Marshall How do you know what is appropriate to use in which instance   Sheryl Ballenger That's determined by the user. If a student attending college will consult with their disability services office together, they, with their disability services coordinator can work out which would be the best for their use. CART does require near verbatim English skills, so that would be somebody who is a very strong reader and who can read to learn. And that's a different skill than just reading for enjoyment. Reading for learning is difficult for some people and then Cprint because of the way it was created by the technical institute for the deaf, because it's developed for a meaning based representation of what's spoken, is typically more of a form that's understandable by people who don't have the ability to really learn everything from reading and want to see that language put in a way that's more understandable. Transcripts are also available for both services, CART or Cprint, so they also kind of serve as a double accommodation so a student can have real time access with CART or Cprint, plus they get notes afterward that they're able to then use for studying later on. You kind of mentioned audio description. It's not really one of the speech to text systems at all, or captioning, but it is used on videos. Audio description is visual information that describes the action, what's being shown on screen, what graphs may include, that kind of thing.   Denise Johnson Marshall So if I'm a department and I have an event and I want to get it captioned, what would be some of the things that I would need to take into consideration? More specifically, what is the difference between closed captioned and open captioned?   Sheryl Ballenger Well, if you're planning an event, first thing you're going to want to do is put out a statement letting your participants know that you're going to have accommodations available. Usually one of those accommodations would be we're going to offer captioning, and when it's an event, it's usually cart because that's more near verbatim and that's what most of the audience is going to prefer not just people who are deaf and hard of hearing. Use cart people who need a little more support to understand what's going on, use Cart as backup for listening once it's determined that Cart is going to be provided as a coordinator or event planner, then you would need to contract with an agency that supplies cart. Once you have contracted with an agency that's going to supply your cart, you're going to need to make sure that the event, whether it's online or in person, has good audio and connectivity for connecting. If it's going to be with a remote service provider. In most cases, that's going to require testing in the beginning just to make sure that you are connecting and that the audio is nice and clear and that the cart captionist is able to understand and hear clearly.   Now you asked about open or closed captioning. Those terms refer to the video captioning or caption media. When video captions are created, the choice is closed or open. Closed captioning means that the user will need to turn those captions on or off. If they choose to use them, they'll turn them on. So YouTube provides a way for turning captions on on a video. Televisions and things that people view screens always have a way to turn captions on or off. But in some cases, when you're showing videos that may be projected on a screen that are used for general information purposes, captions for those need to be open. So open captions are always there, they're burned onto the video. Those captions are not chooseable. You can't turn them off or turn them on.   Denise Johnson Marshall How much time does it take for audio description and what does your team do.   Sheryl Ballenger Regarding the time of how long it takes to have a video captioned or to set something up, or to have audio description added to your video. Video captioning that is accurate starts with a transcript, a correct transcript with punctuation, correct spelling, speaker identification and sound effects if there are any in the recording. Typically, that takes seven to 14 business days. For us at CIDI, section 508 calls for captions that are accurate and synchronized. That means there can't be anything that's not correct in the captions. For audio description, we start with viewing and writing a script of the action or visuals that may be in a film. The script is revised several times to ensure that it is both succinct and that it conveys the essence of the scene that is appearing on the film. Then placement of the lines in the script is determined. We don't want to make a video become longer or too much longer than what everyone else is going to view? Because that wouldn't be fair. We have to find places to fit the description in in the nonadio segments to make sure that audio described film meets our standards and what we want to see. As far as good audio description, that typically takes three to six weeks or so depending on the length of the video and the content.   Denise Johnson Marshall Can you tell us what is the difference between automatic captioning that you may find on a lot of video conferencing platforms versus real time captioning?   Sheryl Ballenger Accuracy is important here. If you were having a low stakes meeting, maybe it's just a small group. The employee is very familiar with everything that's going on in the unit, knows all of the types of systems that are used. This is not a training event. This is just a conversation that's going to happen between employees. Then that might work for using an automatic type captioning service such as something that's included in Zoom. But if you're talking about high stake settings, then the auto generated captions are not appropriate. The problem with auto generated captions is that they do strive for the best guess. If it didn't quite comprehend a word, the system didn't understand the accent of the speaker. It's just going to throw in a word that makes sense in that sentence. But that may not actually be what was spoken and it could actually lead somebody to understand the wrong thing. When we did some tests on some of the auto generated systems that are used in the US, the very best platform scored at 89% accurate. That means that 11% is still inaccurate and it's not fair to the user who's depending on these captions to miss out on 11%.   Denise Johnson Marshall What is the best way to learn more about captioning, audio descriptions or just ways to make your content more accessible?   Sheryl Ballenger The best thing you could do is to just use it. When you watch YouTube videos, turn on the captions if you create content of your own and post to YouTube. Google Help has information where you can learn how to caption your own videos and you'll actually be contributing to the media that's more accessible for everyone. When you do that, you can attend movie theaters that offer caption devices. They even have described audio devices that you can check out from the customer service area and listen to during the movie. All television and subscription service broadcasts now have captions. Most of the subscription services also have descriptions added.   Denise Johnson Marshall Are there any final thoughts that you may have for the Georgia Tech community on your office and your mission?   Sheryl Ballenger Our mission at CIDI is to improve the human condition through equal access to technology based and research driven information services and products for individuals with disabilities. Part of what we do at CIDI is to make sure that we offer many services as well as we conduct research and accessibility. We also house Georgia's Tools for Life program, which is an Assistive Technology act federally funded program. Part of the fun they get to have at work is to use some of these great assistive technology tools that are available and show them to individuals who are interested in learning more about them. Our website is cidi.gatech.edu. That is cidi.gatech.edu.   Denise Johnson Marshall Dr. Ballinger, thank you so much for being a part of our second Beyond Compliance podcast.   Sheryl Ballenger You are so welcome. I enjoyed being here.   Denise Johnson Marshall Let's take a break from this podcast to listen to more about departments that we want you to get to know.   Kendra Brown Get to know the Office of Disability Services for Students. The Office of Disability Services, or ODS, collaborates with students, faculty and staff to create a campus environment that is usable, equitable, sustainable, and inclusive of all members of the Georgia Tech community. If students encounter academic, physical, technological or other barriers on campus, the Disability Services team collaborates with the students to find creative solutions and reasonable accommodations. ODS, located in the Smith Gall Student Services Building, also known as the Flag Building Suite 123, is passionate about providing support and resource information for students with disabilities at the institute. For more information, visit our website at disabilitieservices.gatech.edu or email us at dsinfo@gatech.edu. That's dsinfo@gatech.edu.   Denise Johnson Marshall Now that you know a little bit more, it's time to get back to the podcast. I'd like to welcome our third guest today to the Beyond Compliance podcast, and it's Asha Hagood. Asha is the Senior Project Support Specialist with GTRI. Welcome, Asha.   Asha Hagood Thank you so much for having me.   Denise Johnson Marshall Can you tell us a little bit about your role and your responsibilities?   Asha Hagood As you stated, I work as a project Support specialist Senior on the Organizational development team, and I lead the team's quality assurance efforts for all of the content that we push out, and I also do some program management within that role. We administrate some great programs in support of employee growth and development, like the Career Link program, Job Rotation, Toastmasters Club, and we sit within the Employee Experience team under GTHR. We contribute to the organization's strategic vision by providing high quality, impactful learning experiences. Things that we develop are primarily for our GTRI audience, but we also support campus efforts. Additionally, I'm the Executive sponsor or Chair for the CARES ERG. ERGs Being employee resource groups, I stepped into that role in May of this year.   Denise Johnson Marshall Can you tell me a little bit more about the CARES Employee Resource Group and a little bit about the mission?   Asha Hagood All of the ERGs were established in 2020 in conjunction with a GTRI 2020 Strategic plan. Overall, mission and purpose of all of the ERGs is to facilitate an inclusive work environment, thereby promoting a sense of community and belonging at GTRI, and to create a shared space to strategically impact change. There are a few ERGs cares is one of six ERGs. Apart from functioning as a beacon for employees who require accessibility solutions, as well as for those who are advocates for the accessibility community or caretakers, I like to think that our mission is to cultivate thought leaders in the realm of accessibility and accessibility awareness. We help provide insights to influence decision makers to keep accessibility front of mind One of our members made the point recently that accessibility provisions and mindfulness may seem like an extra step now, but it could and should become a part of your workflow if you create content or manage people.   Denise Johnson Marshall Can you tell us about some of the resources that you provide to employees with disabilities? What are those specific resources that the ERG provides?   Asha Hagood Our strongest resource right now is ourselves and the lending of our voices for employees who may need them. We're a group of about 25. Some folks might be hesitant to speak up about an accessibility need. They may not want to self-identify or be considered a squeaky wheel, but we'd consider it a win if that hypothetical employee will reach out to cares and ask us what we could do to support them. And that support could look like putting them in touch with resources such as CIDI Centers for Inclusive Design Innovation. They're a tremendous resource. As well as the Georgia Library Service, the GLS is also under the USG umbrella. The GLS serves people who are blind or print impaired. Or I could put them in touch with your office or with Dr. Anne Harris. If they're meeting with resistance or running into brick walls, the support of our group could give them a second wind. CAREs could help move the needle.   Denise Johnson Marshall And, Dr. Harris is the compliance advisor who works with our guests that we had on early Langston Jackson.   Asha Hagood Yes, yes, indeed. We've partnered with Dr. Harris on some initiatives, such as the Self Identify campaign. That was an important initiative. The data that bears out from that initiative can help us to launch some programming that would be meaningful to the folks at GTRI.   Denise Johnson Marshall In the CARES ERG. Do you have meetings or is all the information just found online.   Asha Hagood We have a monthly meeting with our members, and we discuss different initiatives that we want to roll out, and we do publicize that within some channels at GTRI. We do a notice to remind members to attend the meeting and to also invite others who just may be curious to come on and attend the meeting as well. Aside from just using the group as a resource or a touchstone, we've got a tip sheet up on our WebWise intranet site and we're going to add some other content there soon. And we're also going to host a screening of the critically acclaimed film Crip Camp, so stay tuned for that.   Denise Johnson Marshall If I work for GTRI and I'm a manager and I wanted to connect an employee to the group, what would be the best way to do that?   Asha Hagood They can search us up on WebWise. Under the Communities tab, all of the ERGs are listed. We have a contact form there. They could reach out to us via that form, or they could reach directly out to me. Asha Haygood by email or slack.   Denise Johnson Marshall That is great. This is definitely a model for the Greater Georgia Tech as well, and it's a great way for us to close out our 50th anniversary of the Rehabilitation act of 1973. As our final question, do you have any final thoughts for us? Just about your program, its mission and its goals.   Asha Hagood I would like to note that we are looking to grow our membership, so that is always a goal. Every voice that comes on board contributes to more diverse thought and reinvigorates our mission. So we're looking for some co-chairs in a couple of areas, and they would serve as the primary contact for outreach and maintaining partnerships and also community engagement. And they would serve as the primary contact for communications, marketing and those related activities. That's what I'd love to leave you with. And also, I thank you so much for extending an invitation to come and chat. Conversations like these will help ensure that accessibility is a forethought and not an afterthought, as one of our cares members recently stated.   Denise Johnson Marshall Thank you. We're happy to have you. And just one final thing, can you just remind all of GTRI again? What is the best way to get the information on this particular ERG or any of the ERGs?   Asha Hagood To get information on any of the ERGs, you would go to the webwise page, and that's GTRI's intranet. Under the Communities tab, all of the ERGs are listed. If you're interested in ours, you would click CARES Erg and that will take you to our page and our resources and my contact information.   Denise Johnson Marshall Thank you so much. I appreciate your time today.   Asha Hagood Thank you so much again Denise for having me.   Denise Johnson Marshall let's take a break from this podcast to listen to more about departments that we want you to get to know.   Kendra Brown Get to know the Office of Equity and Compliance Programs the Office of Equity and Compliance Programs is here to educate, identify and illuminate systemic and institutional barriers to equity and inclusion at Georgia Tech while creating a culture beyond compliance. Our office provides support and investigates matters involving accessibility compliance issues. These issues can include physical or digital accessibility barriers on campus, disability, discrimination, sexual harassment, and sexual violence. Additionally, we provide resources to pregnant and parenting individuals. As a part of our mission to educate the campus community about our office and the work that we do, we offer a series of trainings and workshops. This is to ensure that our campus partners have the tools to support the institutional strategic plan of expanding access and creating a diverse, equitable and inclusive environment. We invite you to collaborate with us as we work together to build a better Georgia tech. To learn more or submit a report of compliance issues, visit our website at diversity.gatech.edu/equityandcompliance.   Denise Johnson Marshall Now that you know a little bit more, it's time to get back to the podcast. I'd like to welcome our fourth guest to the Beyond Compliance podcast. We have Dr. Ken Surin. Ken is the Director of the Excel Program. Welcome, Ken.   Ken Surdin Nice to be here, Denise.   Denise Johnson Marshall Ken, can you tell us about the area of your role within the CEISMC program and then specifically about your responsibilities?   Ken Surdin Excel at Georgia Tech is a program within CEISMC. It's a four year certificate program for students with intellectual and developmental disabilities, and it falls under the classification of Inclusive post-secondary Education.   Denise Johnson Marshall For those who may not be as familiar, can you tell us exactly what is the CEISMC program? Your overarching program that the EXCEL Program is a part of.   Ken Surdin Within Georgia Tech is the center for Education, Integrating Science, Mathematics and Computing. EXCEL is part of that program. EXCEL was started in 2014 and we had our first group of students, a group of eight in a cohort, begin in 2015. There's about 260 programs across the country that are IPSY programs. EXCEL is one of about 40 4 year programs that offer Pell Grants, on campus housing, inclusive clubs, internships and is designated as a comprehensive transition program by the Department of Education. I am the founding director of that program going into my 10th year. Like a lot of directors across Georgia Tech, I am writing grants and raising funds for program needs and scholarships so that we can make sure that our program is both equitable and accessible to students that may not otherwise be able to afford college and be able to attend Excel.   Denise Johnson Marshall Can you tell us a little bit about the history of the Excel program at Georgia Tech, and then also a little bit about some of the other similar programs in higher education that we may have modeled ourselves after or we've exceeded the expectations.   Ken Surdin Great question. Excel was birthed out of the College of Business by Terry Blum, who was the former dean of the College of Business and the founding director of Georgia Tech's Institute for Leadership and Social Impact. Also, Professor Cyrus Auiden from the School of Mechanical Engineering both had a son and a daughter who had an intellectual and developmental disability, and they saw this growing movement across the country of inclusive programs and they thought, Georgia Tech has a standard of excellence. Why not have a program at Georgia Tech that could be as good and hopefully better than any of the other programs that existed out there? They really helped birth the program and then they hired me about a year in advance of having any students on campus to develop all aspects of the program. I had a year to do it and work under the structure of being a pilot program under the provost office. That really is the incubation of EXCEL. Also say that what makes us unique is that most programs like EXCEL across the country are housed within special education centers within a university or college, and they're typically liberal arts institutions.   Ken Surdin Georgia Tech is not a liberal arts institution and the fact that we came out of the College of Business and are now in CEISMC really shows how entrepreneurial the mindset was in creating EXCEL. In fact, all the staff and faculty that are involved with EXCEL have used design thinking to develop the courses, to develop competencies and curriculum and measurement of our outcomes so that we can track individual students progress, students as a cohort's progress, and also our program's progress to make sure that we are constantly under a continuous improvement model. I think that really sets us apart in terms of the programs across the country is the fact that we're tracking what we do, throwing out what doesn't work and improving what does.   Denise Johnson Marshall It also sounds like an asset to have that type of thinking with this program. If there is a student out there who wants to work or volunteer for this program, can you tell us how they could do that? And then also, what does the whole selection process look like?   Ken Surdin Absolutely. We have a full-time mentor coordinator. His name is Luke Roman. He's been with the program for six years. He helps recruit students to work with our students as mentors and coaches. He will take a phone call or an email. You can reach out to him. You can reach out through our website and find out more about how to be involved with the program. I'll also add that the feedback from many of our mentors over the last nine years has been that the experience has helped them in their co-ops and their internships and also gain employment after they graduate. They've been told that employers often ask them about their EXCEL experience, and the reason is that employers are looking to hire people that are collaborative, that can work in groups, that can work with people that may see the world differently, and who are able to quickly understand when somebody may not understand something they're saying and pivot and rephrase what it is they say so that they communicate clearly. They believe that working with EXCEL students has taught them how to do that. Another thing I'll add is that Georgia Tech degree seeking students are the hiring managers and employers of the future, and the fact that they're working with our students means that one day they may be in a position to hire them because they're aware of their gifts and their capabilities and their assets can help carve a job that might be appropriate for them.   Denise Johnson Marshall Sounds like a great asset to be located exactly where we are. Through your ten years of being the director of EXCEL, what would you say are the top three experiences that participants have said have been the best part of their time with the program?   Ken Surdin I would point to students talking about gaining greater independence and independent living skills by living on campus or in many cases, private dorms just off campus, being involved in the community of Georgia Tech, gaining friendships within the program among mentors, improving their social skills, which is an asset for gaining employment, something that we do through an evidence based social skills course that we teach and in which degree seeking students act as mentors. Employment and the opportunities that they gain through their internships on and off campus are something that students get really excited about. And finally, convocation or the graduation ceremony, which is really the cherry on top for all of our students.   Denise Johnson Marshall What does EXCEL's Career placement program look like?   Ken Surdin Great question. I'm glad you asked that. We have three full time career advisors staffed at EXCEL faculty and staff. They teach career courses starting the first semester that a student arrives on campus. Students do internships every semester after that at a minimum of seven internships. Give you an example. I had a cohort of eleven students graduate and they had 96 internships between them by the time they graduated. Their students are taking career courses, participating in internships on campus, at Barnes and Noble, at CIDI, at the Dean's office. They're also participating in internships and paid jobs with over 100 employers that we work with, the Center for Disease Controls, National Center on Birth Defects and Developmental Disabilities. I've had two students intern there. I've had four students intern at Georgia LEND. I've had students intern at Fulton county government, and on and on and on. I could talk about the internships they're involved in. Another thing I'd like to add that sets Excel apart from many programs is that we actually track our graduate employment outcomes from year to year. 93% of our graduates are currently employed. If you look at Bureau of Labor Statistics for 2022, only 21.3% of people with any disability were employed in America, and it was about 19% for the population that we serve intellectual and developmental disabilities.   Ken Surdin The fact that we're at 93% shows that our students are motivated and capable of working and that opportunities need to be put before them so that they can show those capabilities and be participants in the world of work and their communities at large.   Denise Johnson Marshall Are there any final thoughts that you want the Georgia Tech community to know about your program and your mission?   Ken Surdin Yeah, sure. Our mission is Excel at Georgia Tech, providing an innovative, inclusive college experience for students with intellectual and developmental disabilities, awarding professional education certificates, and preparing students for employment and fulfilling lives. One of the other aspects of the program that's really important, especially when it was being founded, was that Terry Blum and Cyrus Aidun wanted to make sure that the program fit within the strategic mission of Georgia Tech as a whole. Improving the Human condition was front and center, and this program definitely supports Georgia Tech's mission and their values and their ethics. One thing that many programs don't do, that we do is provide a whole year of transition courses to prepare students for life after college that cover seven key areas of transition. So, for example, housing. Where are you going to live? Transportation. How are you going to get back and forth to where you live and to your job? Where are you going to work? Health and wellness, Technology. Just some of those, to name a few. But we work on developing a plan for the students, also working with the families to understand what level of support the students will need when they graduate so that they can succeed in the world after college.   Ken Surdin I often say that we are preparing our students for the world of work and to be full participants in their community. But the world of work and communities are not prepared for our students. If you enter with a disability in our program, you're exiting with a disability from our program. And all the challenges that exist for people with disabilities in the world still exist when you graduate from college. We may be better preparing our students for life after college, but all of those challenges are still there as a nation and a state, and as communities, we still have a long way to go to make sure that these students are successful post-graduation.   Denise Johnson Marshall One last time, how can individuals contact you, your office, your program? If they want to know more information.   Ken Surdin You can contact us at excel@gatech.edu. That's excel@gatech.edu.   Denise Johnson Marshall Ken, thank you so much for your time today. It was great to hear about the program and its continued growth.   Ken Surdin Denise, it was an absolute pleasure to be on this podcast and I wish you all the best and hope that you keep doing it.   Denise Johnson Marshall Thank you. Let's take a break from this podcast to listen to more about departments that we want you to get to know.   Kendra Brown Get to know GT Human Resources employee relations at Georgia Tech individuals with disabilities have an equal opportunity to pursue education or employment and to have access to campus programs, activities and services. If you are an employee or visitor and you have a disability and need assistance, we are here to help. The purpose of Georgia Tech Human Resources Employee relations is to one, coordinate, facilitate, and monitor the interactive reasonable accommodation process, or RA plan, which may assist qualified employees in performing the essential functions of their position and two, coordinate Georgia Tech compliance with the employment requirements of the Americans with Disabilities act, or ADA, and with other related laws, policies and procedures and three, ensure qualified persons with disabilities have full and equal access to all terms and conditions of employment, regardless of disability and four, educate staff on their rights and responsibilities under the Americans with Disabilities act and provide technical assistance as needed. For more information, please visit our website at ohr.gatech.edu/disabilityservices or email us at employee-relations@ohr.gatech.edu. That's employee-relations@ohr.gatech.edu.   Denise Johnson Marshall Now that you know a little bit more, it's time to get back to the podcast. Thank you for joining us for our Beyond Compliance podcast. This is the end of our series of the 50th anniversary of the Rehabilitation act of 1973. Join us for future broadcasts on beyond compliance.   Announcer And thanks to everyone joining us for this episode. For more information on this episode's guest and additional resources, check out the show notes for this episode and feel free to contact us via email at podcast@gtri.gatech.edu. If you aren't aware already, please note that the Georgia Tech Research Podcast is now available on Apple Podcasts, Google Podcasts, and Spotify. Tell your colleagues and others who might be interested in Georgia Tech research to subscribe and tune in.    

In this episode, we dive deep into the intriguing relationship between vitamin E, Selenium, and the risk of prostate cancer. Taking center stage is the renowned SELECT trial from the early 2000s, which sparked numerous questions about this association. I'm honored to have Dr. Eric Klein, the study's primary author and former chair of urology at Cleveland Clinic, join me to shed light on this topic. Now engaged in groundbreaking genetic testing for various cancers with Grail, Dr. Klein's insights are invaluable.Together, we delve into the choices made in the study – like using synthetic vitamin E when mixed tocopherols might have been better, or the decision to use Selenium methionine over SEIS yeast. Dr. Klein also shares his enriching experiences at Stanford University's Distinguished Korea Institute, a commendable program tailored for retirees focusing on wellness, community, and purpose. Plus, we journey through the transformation of prostate cancer treatment and understanding from the late 1980s to today.Please tune in for a captivating conversation with Dr. Eric Klein about vitamin E, Selenium, prostate cancer, and the many intricacies of his storied career. Don't miss out!___________________Thank you to our sponsors.This episode is also brought to you by AG1 (Athletic Greens). AG1 contain 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, your nervous system, your immune system, your energy, recovery, focus, and aging. All the things. Enjoy AG1 (Athletic Greens).----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines: XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement Store____________________________________DISCLAIMER: This audio is educational and does not constitute medical advice. This audio's content is my opinion and not that of my employer(s) or any affiliated company.Use of this information is at your own risk. Geovanni Espinosa, N.D., will not assume any liability for any direct or indirect losses or damages that may result from the use of the information contained in this video, including but not limited to economic loss, injury, illness, or death.

In this episode of On Purpose, Janice is joined by Eric Klein, a guest who shares his insights on finding purpose in life. Eric discusses his upbringing in a creative and entrepreneurial family in New York City, where his grandparents started a successful business and his father worked on Wall Street. He also highlights the influence of his artist mother, who exposed him to the world of art from a young age. How blessed he feels his family was so supportive of his journey. Join Janice and Eric as they explore the connection between personal history and finding one's purpose.Connect with Eric at his Website.Follow Janice on Facebook and InstagramEmail Janice: stopdiets@aol.comJanice's Website: http://stopdiets.comIf you enjoy the podcast, please leave a positive rating and review!

In this episode of the Georgia Tech Research Podcast, host Chelsea Selby talks to Erik Andersen, a Principal Research Associate in Georgia Tech Research Institute's (GTRI) Electro-Optic Systems Directorate (EOSD). This episode introduces listeners to the “Hiring Our Heroes” U.S. Chamber of Commerce program, which Connects organizations such as GT and GTRI to the military community to create economic opportunity and a strong /diversified workforce. Through Hiring Our Heroes, GT and GTRI get an insider look at service members' separation from the military and how we bring them into the GT/GTRI community of researchers.  The Podcast discusses what the underlying concepts and principles of military separation are, why they are important at Georgia Tech and GTRI, and what implications these concepts have on the future hiring of military members, their spouses, and other veterans.  Talking Points  In this episode, listeners will hear about:  Who is Erik Andersen, what is his background, and how did he come to GTRI via the HOH Program.  What is the HOH Program and how does it fit at GT and GTRI.  What is an HOH cohort.  What military members are eligible to take advantage of the HOH program.  The formal process used to engage transitioning military in HOH.  What types of experience do these members bring to the table for GT and GTRL  What comes first,--HOH participation or the hiring of candidates at GTRI?  Who pays for HOH members' time.  Key points of contact in the state of Georgia, Georgia Tech, and Georgia Tech Research Institute.  Resources  Links  https://gtri.box.com/s/2e6odt0004muxkwhkucn7e1oc61khqlp (Andersen Bio)  https://gtri.box.com/s/wer36fhd25qwqtr08r5nekt25hyhfkrn (Key HOH Dates 2023/2024)  https://gtri.box.com/s/5p8hy7tk01dkaoutsgw89r19u3fs2c4d (Link to GTRI HOH Overview)  www.hiringourheroes.org (HOH National Program URL)  tdekryger@uschamber.com (Georgia POC for HOH, US Chamber of Commerce)  laura.hessler@asc.gatech.edu (Georgia Tech POC for HOH)    Episode Credits  Host, Chelsea Selby, chelsea.selby@gtri.gatech.edu  Guest:  Erik Andersen, erik.andersen@gtri.gatech.edu   Producer, David Landry, david.landry@gtri.gatech.edu    Announcer, Eric Klein, eric.klein@gtri.gatech.edu    Editors, Christopher Weems, christopher.weems@gtri.gatech.edu; Monica Ngando, monica.ngando@gtri.gatech.edu   Audio Engineer, Amanda Kieffer, amanda.kieffer@gtri.gatech.edu    Email Us  Have feedback or additional questions about the podcast? Reach out to podcast@gtri.gatech.edu. 

In this episode, I interview Eric Klein. Eric is a lineage holder in the Kriya Yoga lineage. He was trained, ordained and empowered by Goswami Kriyananda to share the Kriya Dharma. He's lived this path for 50 years (with his wife Devi) and shared it with over 25,000 people including seekers from every faith tradition and spiritual-but-not-religious folks. Eric's grounded approach appeals to parents, artists, yogis, CEOs, surfers, and political leaders. Listen in as Eric shares:the meaning of “Yoga” and “Kriya”, and his experience of the Kriya yoga practice the three disciplines of Kriya Yoga and the goals of this practicehow Kriya Yoga helps us to heal our karma and the karma of our family how our outward expression is a mirror of our inner integration how to recognise the somatic signals of our reactivity and use these as a guide for recalibration. “If you have a fire in your house, the easiest time to put it out is when it's a spark... The easiest time to heal a relationship is at the initial sense of discord. It's also the easiest time to ignore the discord because it's not that big, and what we do in meditation is, we are cultivating our capacity to respond to subtle indicators with gentle loving awareness.”~ Eric KleinSign up for the 2-session program Return to the Radiance: The 3 Disciplines of Kriya Yoga (June 2023)https://www.wisdomheart.com/essencekriyayogaLearn more about Eric and Kriya Yoga here:https://www.wisdomheart.comhttps://www.facebook.com/wisdomhearthttps://www.instagram.com/wisdom.hearthttps://www.youtube.com/@WisdomHeartTV    Support the showSupport the show so I can keep producing more episodes here:https://www.buzzsprout.com/1756648/supporters/newRate & Review The Wellbeing Room on Apple Podcasts - Click on the Listen on Apple Podcasts button and add your review in the Podcast app. Scroll to the bottom of the page to Ratings & Review and select Write a Review. Get in touch: leah@thecentreofki.com.au

Eric Klein of St. Charles explains True Team track to John & Jim, then John talks about softball, track and Minnesota's new Hall of Famers.Thanks to Minnesota Propane Association (https://discoverpropanemn.com/,) Pizza Barn in Princeton, MN (https://www.PizzaBarnPrinceton.com) & All Energy Solar (https://www.allenergysolar.com/coach)

Eric Klein of St. Charles explains True Team track to John & Jim, then John talks about softball, track and Minnesota's new Hall of Famers.Thanks to Minnesota Propane Association (https://discoverpropanemn.com/,) Pizza Barn in Princeton, MN (https://www.PizzaBarnPrinceton.com) & All Energy Solar (https://www.allenergysolar.com/coach)

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.

Progressive Rock Band Is Back With New Album#newmusic #progrock #newalbum #daysbeforetomorrow #rockmusic  After a ten-years hiatus, the award-winning melodic progressive arena rock band, Days Before Tomorrow, is back with its long-awaited record, Now and Then Part II: Stories and Dreams. The record was recorded years ago but went unreleased as band members went on to pursue other musical projects. Regrouped and reinvigorated, this explosive set of previously unreleased material—freshly mixed by James Linton (Bobby Kimball)—will stun long-time DB4T fans and introduce an entirely new audience of discerning listeners to another epic rock band worthy of their attention.With a vibe that is hard rocking and precise, featuring soaring lead vocals and multi-part harmonies surrounded by technical musical instrumentals that almost require the listener to unleash his/her inner air guitarist and air drummer, it's hard to place Days Before Tomorrow in one basic category like prog metal or arena rock. This is a genre-defying group that appeals to fans of everyone from Kansas and Styx to Porcupine Tree and Dream Theater.Spotifyhttps://open.spotify.com/artist/0KEIdWInHwgqvIjbT65Ahl?si=UFj17Tz0S7GthMbvIC65sQApple/iTuneshttps://music.apple.com/us/artist/days-before-tomorrow/186496275Website: https://www.daysbeforetomorrow.comInstagram: https://www.instagram.com/db4tofficialFacebook: https://www.facebook.com/daysbeforetomorrowTwitter: https://twitter.com/daysb4tomorrowTikTok: https://www.tiktok.com/@daysbeforetomorrowYoutube: https://www.youtube.com/daysbeforetomorrowThanks for tuning in, please be sure to click that subscribe button and give this a thumbs up!!Email: thevibesbroadcast@gmail.comInstagram: https://www.instagram.com/listen_to_the_vibes_/Facebook: https://www.facebook.com/thevibesbroadcastnetworkLinktree: https://linktr.ee/the_vibes_broadcastTikTok: https://vm.tiktok.com/ZMeuTVRv2/Twitter: https://twitter.com/TheVibesBrdcstTruth: https://truthsocial.com/@KoyoteFor all our social media and other links, go to: Linktree: https://linktr.ee/the_vibes_broadcastPlease subscribe, like, and share!

Episode Summary  In this episode of the Georgia Tech Research Podcast, host Scott McAtee speaks with Dr. Carl DiSalvo, associate professor in the College of Computing at Georgia Tech, and Greg McCormick, senior Research Engineer in the Electro-Optical Systems Lab of Georgia Tech Research Institute. This episode focuses on the concept of "smart cities" and what they can mean for society at large. Dr. DeSalvo's work for more than a decade has focused on how communities use technology. For four years, McCormick has been  one of the leaders of the Georgia Smart Communities Challenge.   Talking Points In this episode, listeners will hear about: ·        What are Smart Cities. ·        The areas of impact for Smart Cities, including: economic development, public safety, energy environment, infrastructure and transportation. ·        The Georgia Smart Communities Challenge (Georgia Smart). ·        Public response and “buy in.” ·        Challenges and long-term outlook.   Resources Email Have feedback or additional questions about the podcast? Reach out to podcast@gtri.gatech.edu.    Links https://smartcities.gatech.edu/georgia-smart https://www.carldisalvo.com/portfolio/dataworks   Episode Credits  Episode Team  ·        Host, Scott McAtee, chelsea.selby@gtri.gatech.edu  ·        Producer, Dylan Husserl, Dylan.Husserl@gtri.gatech.edu ·        Editor, Christopher Weems, christopher.weems@gtri.gatech.edu; ·        Announcer, Eric Klein, eric.klein@gtri.gatech.edu ·        Audio Engineer, Amanda Kieffer, Amanda.Kieffer@gtri.gatech.edu  

Have you ever completely lost a day of your life? Joy Askew has: and her per diem was lost along with it. Find out the story behind this and more from Aksew, who in addition to her own music has played with everyone from Joe Jackson to Peter Gabriel to David Byrne, on this week's episode of Fuck This Gig.Hosted by Jeff Miller & Jesse Krakow.Edited by Jesse Krakow.Engineered by Eric Klein.Original Music by Jesse Krakow & Eric Klein.

Listen to ASCO's Journal of Clinical Oncology essay, “Mrs. Hattie Jones” by Dr. Eric Klein, fellow at Stanford's Distinguished Careers Institute. The essay is followed by an interview with Klein and host Dr. Lidia Schapira. Klein shares the mystery of why Mrs. Hattie Jones might have died when she did. TRANSCRIPT Narrator: Mrs. Hattie Jones, by Eric Klein, MD (10.1200/JCO.22.02405) That Hattie Jones died was not unexpected, but why she died when she did has been a mystery for more than 40 years. It was late summer and she'd been hospitalized for several weeks when I met her, as it were. In the era before a palliative care subspecialty was established, patients with incurable cancer like Mrs Jones were admitted for inevitably long hospital stays characterized by slow declines in form and function, managed by trainees like me, the least experienced and least expert on the team. The chief resident on the service, burly and gruff, brought us into her private room early on the first day of my rotation on the colorectal surgery service. Mrs Jones appeared malnourished and frail, with one intravenous (IV) bottle hanging and concentrated urine collecting in a bag at the bedside. She did not, in fact could not, acknowledge our presence or answer our queries as to her well-being or needs because of an induced somnolence by the morphine running continuously in the IV. She breathed regularly but slowly and did not seem to be in distress. The goal in caring for her, we were told, was simply to keep her comfortable until she died. She was the first terminally ill patient I'd cared for, and her isolation and unresponsiveness filled me with sadness and unease. Alone on afternoon rounds later that day, I was surprised to find someone sitting beside her bed holding her hand. The visitor was a sturdy woman a few years younger than Mrs Jones, dressed neatly and respectfully as though she were in church. She looked at me and said, “I'm Hattie's sister, and I'm here to be with her when she dies.” Her demeanor conveyed a sense of duty both to her sister and herself, and her solemnity evoked a divine presence. I introduced myself and answered her many questions about her sister's condition.  “Was she in pain?” It did not seem so, I replied. “Would she ever wake up?” I explained we could wake her up by turning down the morphine but that she would likely be in pain if we did. She considered that silently for a few moments and said she did not want that, although she longed to hear her sister's voice again. “Was she getting enough nutrition?” The IV also contained sugar water with enough calories for her condition, I explained. She said she missed her sister's smile. “How long is she going to live?” I admitted that even experienced physicians could not predict that. She was silent after that and after a few minutes I excused myself to tend to other patients. The days turned into weeks, then months, as the daylight hours grew shorter and the weather cooler and the fall slowly turned into winter without much change in Mrs Jones' condition. I'd greet her on rounds each morning, never eliciting a response, briefly examine her, write new IV orders, and move onto the day's work—rounding on patients being prepped for or recovering from surgery, then outpatient clinic, the operating room, and new patient admissions. Each afternoon Mrs Jones' sister was there by her side for several hours, watching her intently, holding her hand, and sighing sadly. Each day she reminded the team “I just want to be with her,” she said, “so she will not be alone when she passes.” Days on call for me were generally stressful and lonely, testing my medical knowledge and incompletely developed sense of empathy. As interns and newlyweds, my wife and I had call schedules that did not match—she every third night and me every fourth, such that we only had one evening a week together that first year when neither of us was exhausted. I missed our days in medical school when we shared classes, had dinner together every night, and walked afterward to the local Baskin- Robbins; now we work in different institutions, with different hours, and rarely had enough energy in the evenings and on weekends to truly be present for the other. I drew the short straw on my team in late December and was on call on Christmas Day. Because the operating room and clinics were closed, I made rounds later than usual and Mrs Jones' sister was already at her bedside when I entered her room. She told me she came early because she was hosting her large family for an early afternoon Christmas dinner, a long family tradition. Over the months of Mrs Jones' hospitalization, we'd developed a sense of each other, she trusting an inexperienced, young, and tired doctor trying to keep her sister comfortable, me seeing a devout woman dedicated to her sister's soul. She asked, “Is it safe for me to leave Hattie alone for a few hours this afternoon so I can have Christmas dinner with my family?” and added that it would be the first without her sister's presence in many years. I replied assuredly that it was, that her sister's condition had been stable for many months and that I thought she was going to live for a least a few more weeks. She looked at her sister, then at me, gathered her coat and scarf, kissed Hattie goodbye, and headed home. The rest of the day was relatively quiet for a day on call but typical for a holiday. There were a few patient phone calls, one or two patients to be seen in the emergency room, and no emergency surgeries. The hospital provided a free meal of turkey and sides to all the staff that were on call, and those of us in the cafeteria shared a sense of holiday cheer, albeit muted by being away from our own families. Despite the happy spirit there, I was lonely, missing my wife, and sad to have to postpone my own Christmas Day birthday celebration. While thinking about that I got what I thought was a routine call from the colorectal surgery nursing unit—perhaps about a patient needing a medication reorder, or a need to restart an IV, or to talk with a family about a hospitalized relative. Instead, the nurse on the phone summoned me to the unit to pronounce Mrs Jones dead. I paused for a long moment before asking, dreading the response: Was Mrs Jones' sister back from Christmas dinner? “No”, came the answer. My tears flowed copiously and quickly; my heart hit the floor. I sobbed loudly for a few minutes, unable to explain to my colleagues what had transpired. The walk from the cafeteria to the nursing unit seemed much longer than usual. I examined Mrs Jones for the final time and confirmed her lack of heartbeat and breathing. I watched as the nursing staff disconnected the IV, a lifeline that was no longer needed. I sat at the nursing station and filled out the death certificate. Name: Hattie Jones. Age: 63. Date and Time of Death: 1:23 pm, December 25, 1981. Cause of death: Cardiopulmonary arrest secondary to metastatic colon cancer. I put down my pen and summoned the courage needed for my last task—telephoning Mrs Jones' sister to share the news. I do not recall what I said, but I have a vivid memory of the reaction—she was initially silent and then I heard her cry, others in the background joining in when she repeated the news; I remain unsure to this day which one of us was more despondent. Over the course of my career, I've pondered many times over the timing of Mrs Jones' death. Perhaps she wanted her sister to be surrounded by family when hearing the news so that the burden of her sister's grief would be lessened by sharing. Perhaps it was meant to serve as a poignant reminder about the need for and power of celebrating time with family. Perhaps it was for me to experience a sense of helplessness to deepen my empathy for those who were incurable. Perhaps it was all these reasons or perhaps none of them. No matter the reason, after a career caring for thousands of patients, seeing many suffer and die along the way, I have never experienced a sadder moment. Why Mrs Hattie Jones died when she did is an enduring mystery, but her memory, the profundity of the bond between these two sisters, and the empathy I learned from them have lived on and helped me navigate the emotional ups and downs intrinsic to the practice of oncology. Dr. Lidia Schapira: Hello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the field of oncology. I am your host, Dr. Lidia Schapira, associate editor for Art of Oncology and a professor of medicine at Stanford University.  Today we are joined by Dr. Eric Klein, a fellow at Stanford's Distinguished Careers Institute and Emeritus Professor and Chair of the Glickman Urological and Kidney Institute at Cleveland Clinic. In this episode, we will be discussing his Art of Oncology article, ‘Mrs. Hattie Jones'.  Our guest's disclosures will be linked in the transcript.  Eric, welcome to our podcast and thank you for joining us. Dr. Eric Klein: Thanks for having me. It's great to be here. Dr. Lidia Schapira: Let me start by asking you a little bit about your process for writing narratives. When do you write, and what kind of scenario triggers your desire to write? Dr. Eric Klein: I haven't written anything creative like this since college, so I don't really have a process. But I can tell you the process I used for this particular piece. I had the real pleasure of being in John Evans' class. He's a faculty member at Stanford in the English department who taught memoir writing. And so the class was to teach us how to write memoirs, and it was filled with prompts, which was a wonderful way to respond, and it tapped into some creativity that I didn't know I had.  So the prompt for this particular piece was to write about a secret or a mystery. And I thought about it for a day or two, and I thought, I have lots of secrets in my life, but I don't really want to share them with anyone. And I struggled with it. So I was having dinner with one of my classmates, Thanya, and just discussing this because she had taken the class, and she said, "Well, why don't you make it a mystery?" And it clicked immediately, as I have written, is that this mystery about why Mrs. Jones died when she did has stuck with me for more than 40 years.  So that night, I was lying in bed trying to figure out how I was going to write this because I'm not a creative writer--tossing and turning. And about 1:30, I got out of bed, and I sat in our dark living room, and I tapped the story out on my iPhone, and I emailed it to myself, and I edited it the next day. And that was the process. Dr. Lidia Schapira: Your essay has this very factual title, including the Missus, ‘Mrs. Hattie Jones'. And then it starts with this statement, "She died.” We know this, but her death is not unexpected. But the timing was. And that mystery has stayed with you for 40 years. It's a very impactful opening. I thought that was very creative, actually, on your part. Beautifully done. Tell us a little bit about why you have pondered for 40 years about the timing of Mrs. Jones' death. Dr. Eric Klein: It was a very emotional event for me, in part because I was so young in my career. I had never taken care of terminally ill patients before. Nothing in medical school prepared me for that. There was no palliative medicine service at the time. And I think, as many social scientists have observed, is that things that happen to us when we're young, like our first love, always stick with us more firmly and more deeply than things that come later in life. So that's why it was so emotional for me, and I think that's why it stuck with me for so long. I didn't know how to deal with it at the time. Dr. Lidia Schapira: Did you ever have a conversation with Mrs. Hattie Jones? Dr. Eric Klein: Well, I tried. I certainly spoke with her sister a great deal, but Mrs. Jones was unresponsive, and that was by design. The morphine in the drip, and the IV drip was meant to keep her comfortable. I mean, we have learned a lot about palliative care in the intervening decades, so we don't do that anymore. But that was the standard of care then. Someone was in pain, and so you gave them enough narcotic medication to keep them out of pain, and whatever else happened downstream didn't matter.  I'd say one of the other powerful things about this and sort of the key event of learning that her sister was not at her side when she died was that the whole goal of care was all focused on making that happen and facilitating things for her sister and keeping her up to date. And the nursing team was on board with that and so forth. I felt like it was a big team letdown that we let this woman down and we let her sister down. Dr. Lidia Schapira: Let's talk a little bit about you at that very tender phase of your development. You're a young intern, and you've let your patient and the team down. How did you deal with that? And how have you since processed how you dealt with that? Dr. Eric Klein: This was the saddest thing that's ever happened to me. It was the saddest thing at the time. And I think in reflecting upon my career, seeing many sad things, this still resonates with me as the saddest thing ever because of the deep personal disappointment that went along. I don't have clear recollection of how I dealt with it at the time. Probably I just was sad for a few days and moved on. I mean, being a surgical intern in 1981 was very busy. We didn't have a lot of the ancillary services that we have now. The surgical service was busy, and so we moved on day to day.  This memory just popped up to me every now and then in quiet times and in discussions, in group discussions with colleagues about challenges that we faced in our career, and sometimes in talking to young people about careers in medicine and what you might experience and so forth. And so I guess I dealt with it intermittently through the years and ended up scratching my head. And finally, this was a cathartic experience for me to be in memoir writing, to be able to put this down on paper and, I hope, deal with it finally. Dr. Lidia Schapira: You make a very powerful case for storytelling as part of a practice of dealing with situations that are so emotionally complex. Forty years later, what advice would you give a young intern who is also facing a moment of extreme personal sadness and grief, and disappointment? Dr. Eric Klein: Yeah, my advice would be don't be stoic about it. That was certainly the expectation in the era that I trained. It was certainly the expectation for men. There weren't many women surgeons then, but that was certainly the expectation for men. People died—surgical mistakes happen—and we were just told it's part of the game. And I recall my chief of service telling me it puts hair on your chest. It sort of makes you a man, and so you just deal with it.  So there are so many resources that are available now and a very, very different attitude about the personal part of being a physician and dealing with disappointment and other struggles and the learning curve and all of that. So I would say to youngsters, seek out help—seek out your colleagues who might have been through it. Seek out more senior people and seek out non-physician support people who are generally available at most medical centers and medical schools to help people deal with this, talk about it, and come to terms with it sooner than 40 years. Dr. Lidia Schapira: I'm curious to know if you enjoy reading narratives written by other physicians that describe similar experiences of grief and loss. Dr. Eric Klein: I always have. So the Art of Oncology, A Piece of My Mind in JAMA, and I edit a journal called Urology, and we have a section on narrative medicine. And I think that enriches the experience for the entire medical community and helps keep us focused on our real goal, which is caring for patients. And I think that's increasingly hard in the reimbursement-driven productivity era that we live in now. And that's why I think it's important to do that. Dr. Lidia Schapira: How much have you shared about this creative, reflective side of yourself with your trainees over the years?  Dr. Eric Klein: I hope it came through. I can't say that I know for sure that it did. I guess I was known during my career as a storyteller, and I would often share anecdotes usually related to more clinical which is facing this clinical problem and how do you deal with it surgically, how do you deal with it medically, that sort of thing. And maybe less about specific patients. So it's probably better to ask my trainees if I did a good job with that. Dr. Lidia Schapira: Let's go back to this idea that storytelling is very powerful to help us in communicating with each other and processing experiences. Do you use storytelling, or have you used storytelling with your patients in the clinic?  Dr. Eric Klein: Yes, frequently. My career was mostly focused on prostate cancer, and so when I saw a new patient with prostate cancer, even if it was the most indolent kind, the very first question on their mind always is, "Am I going to die from my cancer?" And I would say I've seen lots of patients, and I'll tell you what the extremes are. I saw one patient with lymph node-positive cancer who's still alive 25 years after his initial treatment and living a normal life. And I saw one patient with really advanced cancer who died after 18 months. And I would say to them, "Your experience is going to be someplace in between those two stories." Or there might be a more specific situation of someone facing a particular treatment or surgery and they're concerned about that, and I would even hook them up with other patients who have been through it so that they could experience the story from the horse's mouth, so to speak. I think it's an important part of managing patients, I do. Dr. Lidia Schapira: So let's talk a little bit about the language and the plot in those stories. What kind of metaphors do you use, if any?  Dr. Eric Klein: Well, I had one patient tell me that I spoiled his taste for oranges because when I described the prostate, I described it like an orange with a rind or a capsule on the outside, and the cancers in the fruit in the middle. So that was one that didn't resonate ultimately. Then I switched to lemons since no one seems to like lemons and so forth. I would say the stories generally had a good outcome. Patients want their physicians to be optimistic, and certainly, patients facing cancer want their physicians to be optimistic. And I'm sure I had a lot of other specific stories to tell about specific patient experiences that don't come to mind readily now.  Dr. Lidia Schapira:  What book have you read recently that you've enjoyed and would recommend to others? Dr. Eric Klein: I would say Evil Geniuses, which is not a medical story at all. It's a story about the conservative political movement and the Federalist Society, and big business that set an agenda back in the Reagan era to take all the negativity around capitalism and conservatism out and to relax restrictions on business. And to fill the Judiciary with conservative judges and so forth, and how they have succeeded over the course of those decades to where we are now. I have to say I don't read much fiction. I honestly, I don't find fiction does much for me. I read mostly nonfiction.  Dr. Lidia Schapira: You come across as somebody who is very self-aware, and I assume it's taken a long time to be able to say things about your feelings and recognize the impact some of these patient experiences have had on you. And in the essay, you also mentioned that your wife is a physician and that you spent a lot of time together in medical school, but then the paths diverged. And I'm interested in knowing if these sorts of stories about patients came to your dinner table. Tell us a little bit about that. Dr. Eric Klein: Yeah, all the time. Actually, over the course of our careers, we would definitely share the highlights and the lowlights of our day and talk a lot about specific patients and the problems that they faced and what we learned from that. And I learned a lot from listening to my wife. She was a pediatric neurologist, so didn't deal much with cancer, but I learned a whole lot more about social determinants of health and how social circumstances really impact the patient's ability to cope with a serious diagnosis and recover from it and so forth. Because she dealt with children who came mostly from impoverished families and didn't have the same sort of family or social service support as the kind of patients that I saw, who were mostly Medicare or private insurance patients. Dr. Lidia Schapira: I must finish this interview by asking you why you think Mrs. Hattie Jones died when she did. Dr. Eric Klein: That's a great question. I think the most likely explanation, without really knowing her, but with knowing her sister and understanding the family dynamics, is that she really did not want her sister to hear the news when she was alone in the relatively impersonal environment of the hospital. Whether or not that's true, I don't know. But that's what I had chosen to believe, that she wanted her sister to hear the news when she was surrounded by her loved ones and her family. And I think that resonated nicely with the idea that I wrote about, which is being away from my family on Christmas Day and on my birthday and so forth, and being isolated and alone and how important family is to one's personal well-being and success. Dr. Lidia Schapira: I like your interpretation. I find it both wise and compassionate. And with that, I want to invite you to share with our readers why you decided to send this story out into the world. I understand the reason for writing it. What made you decide to share it and publish? Dr. Eric Klein: So let me start with a call out and a shout out to one of my other classmates, Julie, who convinced me to take memoir writing. My wife had taken it and had a good experience with it early in the DCI experience. And I was reluctant because I've only written clinical papers and scientific papers, and I just didn't sense that I had this creativity. So thank you, Julie, for convincing me.  I shared it because of the reaction I got from my classmates. The dynamic in the class was to share it with a certain number of classmates, and then we were all asked to write a constructive critique of the stories that we've written so that we could get better in memoir writing. But the emotional reaction to this, to my non-physician classmates, was so powerful, and my own reaction to it in writing it. I just read over the proofs that came the other day, and I was crying again, even though I know the story well and have been over it many times, and I thought, "This is something that might resonate with other people. This might be a universal experience." And so it was more of a lark than anything else. But I just thought the world might get something useful out of this. Dr. Lidia Schapira: Well, it resonated with your editor. One of the tests that I usually use when I read the manuscript is whether or not I'm getting teary or whether I'm feeling anything, and it certainly evoked a lot of emotion. So. Thank you, Eric. Thank you for sending it to us.  So until next time, thank you for listening to JCO's Cancer Stories: The Art of Oncology. Don't forget to give us a rating or review, and be sure to subscribe, so you never miss an episode. You can find all of ASCO's shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio  Dr. Eric Klein is a fellow at Stanford's Distinguished Careers Institute and Emeritus Professor and Chair of the Glickman Urological and Kidney Institute at Cleveland Clinic.

Eric's links:https://www.wisdomheart.comhttps://www.facebook.com/wisdomhearthttps://www.instagram.com/wisdom.hearthttps://www.youtube.com/@WisdomHeartTVEric is part of my group coaching program: https://www.georgekao.com/group Comment on this episode:https://youtu.be/IlBtz9rrzDM

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD While the state of cancer screening hasn't seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.

Recommend this show by sharing the link: pod.link/2Pages Malcolm Gladwell famously made popular the idea of 10,000 hours of practice for mastery in his book Outliers. This comes with all sorts of caveats, but the concept holds up an interesting mirror. The other day I was asked, ‘How do you start writing books?' As I attempted to give an answer, I realized that I'd been writing to find my own voice for 40 years now. I must have written about a billion sentences by now, and I've come to understand where my edge is. Perhaps that's what mastery is - not a completion but rather an increasingly subtle understanding of where you're honing the edge of yourself and your craft.   Eric Klein is first and foremost a dear friend and returning guest, but also a spiritual teacher and author. Five years ago, I'd have added that his focus is geared towards bringing greater spirit, mindfulness and meaning to the workplace, but that's shifted a bit since then. Presently, Eric offers the same through his community at Wisdom Heart, helping people to be on a spiritual path, while still walking in the world. Get‌ ‌book‌ ‌links‌ ‌and‌ ‌resources‌ ‌at‌ https://www.mbs.works/2-pages-podcast/    Eric reads two pages from The Bhagavad Gita. [reading begins at 18:05]   Hear us discuss:  The task of rejecting the conventional path to pursue the call of spirituality: “I thought I could ‘hack' the process and not come to terms with my inheritance.” [9:49] | Undergoing spiritual experiences without crisis. [26:14] | How to manage your expertise: “To be a good teacher, always have part of your mind in the student's seat.” [32:32] | “Reality can only wake up in your life as you.” [38:22]

Fruition's Jay Cobb Anderson has literally seen it all: he spent the early part of his musical journey busking on the streets, and with his acclaimed extra-harmony-laden newgrass/folk band, has made it all the way to Red Rocks. Along the way, he's had his share of shitty shows, but it's his best one: a 24 hour, late plane, multi-gig day, that may actually make you want to say “F—- This Gig!”Hosted by Jeff Miller & Jesse KrakowOriginal Music & Editing by Jesse KrakowEngineered by Eric Klein

Composition by Eric Klein.  "I chose to concentrate on just "8 bars" of my staccato typewriter sample (it's actually two splices of "4 bars" stuck together.) Listening to this loop in my MPC sampler, I tapped out a tempo and worked from there. Now I took this sample of mechanical rhythm, and one "bar" at a time, I reproduced the hits of the typewriter keys as hits of Control Voltage (electrical signal that can be interpreted as musical information by a type of synthesizer or drum machine). Now I played around for a couple of days with inputing that CV into some of my synths. "I made a handful of long recordings of this playtime,  jamming with different ideas, enjoying the discovery of a slow turn of a knob, or patching different electronic signals into unlikely inputs and listening listening listening to the results in real time. I am experimenting. I am in dialogue with my gear. Later in the day I will listen back to these long recordings while taking a walk or reading a book and see if I can't decide which ideas were worth repeating. "I settled on an instrumentation. I recorded about 17 minutes worth of this final configuration and then slept on it. The next day I cut together a version under 4 minutes using primarily two of the final takes (with a 4 bar "bridge" from an earlier 37 minute take with an alternate melody and instrumentation)." This is part of the Obsolete Sounds project, the world's biggest collection of disappearing sounds and sounds that have become extinct – remixed and reimagined to create a brand new form of listening. Explore the whole project at https://citiesandmemory.com/obsolete-sounds

Eric talks about finding the correct balance in your business as a developer.

July 23, 2022 In 1890, the Lighthouse Board recommended a lighthouse at Forty Mile Point, on the northeast coast of Michigan's Lower Peninsula. The primary reason for the light was so that as mariners traveled along the western part of Lake Huron between Mackinaw Point and the Saint Clair River, they would never be out of viewing range of a lighthouse. The name of Forty Mile Point stems from the fact that its location is 40 miles southeast of Mackinaw Point. The light station began service in 1897, with a square tower centered on the lake-facing side of a duplex keepers' house. Forty Mile Point Light Station, Michigan. Photo by Jeremy D'Entremont. Pat Williams. Photo by Jeremy D'Entremont. The station was automated and de-staffed in 1969. Two years later, the property was deeded to Presque Isle County, except for the lighthouse building itself. Finally, in 1998, the lighthouse was transferred to the county. Since then, the county and the Forty Mile Point Lighthouse Society have been working to restore the entire site. The park is open year-round to the public. One apartment in the lighthouse is occupied by a full-time caretaker; the other apartment is now a nautical museum staffed by volunteers. Pat Williams is the vice president of the Forty Mile Point Lighthouse Society, and Eric Klein is the resident caretaker at the light station. Eric Klein and his wife, Lisa. Photo by Jeremy D'Entremont.

The Altar Rosary Sodality of Sacred Heart of Jesus Church in McCartyville invites you to join us in praying the Luminous Mysteries of the rosary in loving memory of Diana Goettemoeller and Eric Klein.

I'm very excited to be speaking to Eric Klein. He has been part of my mastermind group for the past 10 years or more, and is a real pioneer in mindful leadership and coaching. He was talking about bringing mindfulness into the workplace before "mindfulness" was even discussed in the corporate world.

Eric Klein and Evan Klein are twin brothers, experts in the crypto, metaverse and real estate industry and young Canadian entrepreneurs who have launched MetaSpace REIT - the first tokenized metaverse real estate investment group whose mission is to provide accessibility for users to get involved with real estate in the metaverse. Eric Klein is the founder and CEO of MREIT and KleinCap Investments. Eric has over ten years of combined experience in real estate and crypto and has led expansion for numerous funds and companies in Canada. Additionally, he has worked on the formation of a traditional REIT in his early 20's. Evan Klein is the COO at MREIT and oversees MREIT's strategic operations and brand vision. Evan has worked with major companies like Compass, KW, and Sothebys. Entrepreneurs are the backbone of Canada's economy. To support Canada's businesses, subscribe to our YouTube channel and follow us on Facebook, Instagram, LinkedIn and Twitter. Want to stay up-to-date on the latest #entrepreneur podcasts and news? Subscribe to our bi-weekly newsletter

Welcome Back to The Gun Room! We have the opportunity to go to Brays Island in South Carolina where we visit the home of Eric Klein, the keeper of a very fine collection of early American side-by-side shotguns. Both originally from New Jersey, Eric and Joel cover a variety of topics including the philosophy of collecting vs accumulating as well as some good discussion with a focus on Parkers and Ithacas. Eric takes us on a tour of his gun room and shows us some very unique guns in his collection. 

Michael's new book How to Begin: Start Doing Something that Matters is now available at www.HowToBegin.com. I was in a mastermind group for about 15 years - we were a gathering of people who had something in common, but there was also a lot we didn't have in common. An enduring friendship from that time is the one I have with Eric Klein, someone who is very precious to me, someone I love having in my life, and someone who's just a mensch. Get‌ ‌book‌ ‌links‌ ‌and‌ ‌resources‌ ‌at‌ https://www.mbs.works/2-pages-podcast/  Michael reads two pages from his upcoming book, ‘How To Begin.' [reading begins at 6:35] Hear us discuss:  “There is an individual greatness that you are here to incarnate, express, and live out.” [11:23] | Owning your qualities. [11:58] | The shadowy side of qualities: “The quality will not care how it comes about, it's gonna follow the architecture of your psyche into the world.” [14:36]

JOIN THE MANIFESTATION CLUB MEMBERSHIP : https://www.marleyrose.ca/manifestationclub ENTER THE FREE MANIFESTATION CHALLENGE HERE! In today's episode of the Money, Mindset & Manifestation Podcast, Marley sits down with Eric Klein a business owner and crypto expert to talk all about living the international lifestyle, doing business online, and of course, crypto. Eric talks about: How to start investing in Crypto Going from Corporate to International lifestyle What are NFTs? Are they just hype? How to live Tax-Free And much more! Connect with Eric: Instagram His Business An international tax expert Waitlist for coaching: www.marleyrose.ca/coaching Try Inward Breathwork FREE for 7days Want to get a FREE money Hypnosis? Add an honest review to Apple, what you think about the podcast and if it's helped you in any way Screenshot your review right away and send it to hello@marleyrose.ca Wait for the magic to arrive in your inbox! In case you missed her last episode! Follow along with Marley at @marleyroseharris or send her an email to Hello@marleyrose.ca!

Returning guest, Dr. Eric Klein, Chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic discusses new 20-year outcomes from a development study of the Oncotype DX Genomic Prostate Score® (GPS) test that was recently published in JCO Precision Oncology (March 2021). The study highlights the role of the GPS test, the only genomic test for prostate cancer with 20-year outcomes, in assessing the risk of long-term distant metastases (DM) and prostate cancer-specific mortality (PCSM) for patients with localized prostate cancer. Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate, testis, and kidney. For several years, including the current edition, Dr. Klein is listed in Best Doctors in America. Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international universities. He was the National Medical Study Coordinator for the National Cancer Institute-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein is the editor of Urology and has been the recipient of numerous awards from the American Cancer Society, the University of Pittsburgh School of Medicine, and the Cleveland Clinic. Dr. Klein received his medical degree from the University of Pittsburgh School of Medicine in Pennsylvania. He completed his residency in urology at Cleveland Clinic and a fellowship in urology at the Memorial Sloan Kettering Cancer Center in New York. #GenomicProstateScoreTest #GPSTest

Eric Klein is a KW Team Leader in Geneva, IL. Caryn sits down with him to discuss his journey, what he has learned, what has changed inside his world, and how he has been exposed to bigger thinking and more opportunities...in other words, he "get's it". It's not about the money- and here you will get to know that in a personal way...his passion, his heart show through in this interview. Enjoy! --- Send in a voice message: https://anchor.fm/messyempire/message

MSHSL prep sports guru John Millea talks BeTheLight and welcomes St. Charles track coach Eric Klein for a discussion on coaching and community amid social distancing.Thanks to PizzaBarnPrinceton.com, which continues to provide food, including delivering chicken dinners to senior citizens.

While Rabbi Yisroel Bernath gives a brief cameo in this episode, Cholentface and the Mzoinoiser Rebbe interview his Dad, and Eric Klein. Together, they discuss the weekly Parsha (Torah portion), golden calves, Rebbes, Zvi's soccer skills, and Dan's Ohel story.

Audio Interference is excited to be bringing you an episode from a guest podcast, Radio Survivor. Radio Survivor is a group of individuals organized to shed light on the ongoing importance of radio. They have a weekly podcast where they interview people involved in wide-ranging and international community radio efforts. Back in July 2019, Interference Archive volunteers Celia Easton Koehler and Elena Levi spoke with Jennifer Waits and Eric Klein of Radio Survivor about our latest exhibition at Interference Archive. It's called Resistance Radio: The People's Airwaves and it's about the history of radio as a medium for grassroots movements. They spoke with Radio Survivor about the stations, communities and contexts featured in the exhibition, and the process, labor, and networks involved. Some of the seeds of our research actually came from Radio Survivor interviews! Resistance Radio is on view at the archive through September 29. If you are in New York, come check it out during our open hours: Thursday 1-9pm or Friday through Sunday 12-5pm. You can also check out our website for events or look out for recordings from some events in the fall season of Audio Interference. A huge thank you to Erik Klein, Jennifer Waits, and everyone from Radio Survivor for speaking with us about Resistance Radio: The People's Airwaves. More information about Radio Survivor and the original interview: radiosurvivor.com www.radiosurvivor.com/2019/07/30/pod…ples-airwaves/ More information about Resistance Radio: The Peoples Airwaves: interferencearchive.org/resistance-ra…les-airwaves/ resistanceradio.online Produced by Interference Archive.

Hello, Eric Klein here. This week’s episode of the radio show features wall to wall music selected by Matthew Lasar to demonstrate his passion for the radio format he would like to hear more of in the world, Hybrid Highbrow. All that music would be against the rules in a podcast, so this web-only version […] The post Podcast #205 – A Brief Update appeared first on Radio Survivor.

Radio Survivor celebrates 10 years on the internet and four years podcasting with our 200th episode. Matthew Lasar joins Jennifer Waits, Eric Klein and Paul Riismandel for this review of the last decade in radio that matters. Matthew tells the Radio Survivor origin story that sprang forth from his I.F. Stone inspired research deep into […] The post Podcast #200 – How We Survived a Decade of Independent Publishing appeared first on Radio Survivor.

In addition to co-hosting the show, Eric Klein edits most episodes, and is a professional freelance audio editor. He put some of his philosophies of editing radio and podcasts in writing for last year’s Grassroots Radio Conference, and for a recent post at Radio Survivor. On this episode Eric elaborates on his advice to “know […] The post Podcast #177 – Philosophies of Podcast & Radio Editing; Seattle’s Rich High School Radio Scene appeared first on Radio Survivor.